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ABSTRACT 
 In order to advance understanding of the brain, more specific and widely applicable 
methods are needed for genetically defining and labelling neuron subtypes in vivo. This 
dissertation describes the development and application of a novel strategy for designing 
viral gene delivery vectors that target and classify specific neurons in the adult rodent brain 
based primarily on endogenous microRNA (miRNA) expression profiles. We call these 
vectors microRNA-guided neuron tags (mAGNETs).  
We first demonstrate the feasibility of using neuron-type-specific miRNA profiles 
to guide viral-mediated transgene expression. Using lentiviral (LV) vectors bearing 
“signature” miRNA recognition sites, we explore several microRNA cassette design 
principles from a synthetic biology perspective and demonstrate the feasibility of 
preferentially targeting inhibitory (GABA+) neurons in the mouse cortex.  
Next, we maximize interneuron targeting specificity by altering the strength of the 
constitutive promoter driving transgene expression and switching the viral packaging 
platform from LV to adeno-associated virus (AAV), producing a GABA mAGNET that 
can label cortical interneurons with 98% targeting specificity in the mouse brain. The utility 
of this GABA mAGNET is highlighted by demonstrations of inhibitory neuron targeting 
 
 ix 
in a Ube3a 2X Tg mouse model of autism, cross-species functionality in the rat cortex and 
hippocampus, and viral-mediated dual-color optogenetic manipulation of two separate 
neural subsets in the mouse cortex.  
Finally, we design and implement a mAGNET vector to characterize a novel neuron 
subtype: calcium/calmodulin dependent protein kinase II alpha (CamKIIα) neurons with 
low expression of miR-128.  Calcium imaging in behaving mice, slice physiology and 
immunofluorescence characterization reveal that low-miR-128-CamKIIα+ (Lm128C) cells 
exhibit several unique biophysical properties, and resemble fast-spiking interneurons. This 
work highlights the potential of mAGNETs to help define neuron subtypes, and 
characterize neural activity and physiology.  
Overall, this dissertation presents a novel platform for viral-mediated, neuron-type 
specific labelling based upon endogenous miRNA expression, provides a useful tool for 
targeting cortical interneurons in the rodent brain with high specificity, and demonstrates 
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CHAPTER 1 - INTRODUCTION 
 
The prevalence and disease burden of neurological disorders have continually 
increased in the U.S. over the past several decades, and this trend is expected to escalate as 
the population ages [1, 2]. Therefore, more detailed knowledge of brain function in both 
health and disease is essential, in order to inform the generation of more effective 
treatments. Understanding the large diversity of cells in the brain and how to access them 
in living tissue are essential steps towards this goal. More specific and broadly applicable 
methods for genetically defining and labelling neural subsets are needed to facilitate in vivo 
characterization of neural physiology and function, especially in light of the increasing 
repertoire of powerful genetically encoded neurotechnologies available [3-6]. This thesis 
is concerned with the development of a viral gene delivery platform that utilizes 
endogenous miRNA expression profiles to genetically target and classify neural subtypes 
in the rodent brain.  
 
1.1 Neuron Subtype Classification 
The brain is composed of many diverse cell types that together give rise to its 
complex functions. Understanding neural diversity and being able to label defined neuron 
subtypes in the living brain is essential for conducting neuroscience research. Considerable 
effort has been made historically to describe neuronal diversity and cell types. In fact, 
Ramon y Cajal’s “Histology of the Nervous System of Man and Vertebrates”[7], which is 




to classify neurons. Since Cajal’s time, researchers have classified neuron subtypes based 
on many biophysical properties, including morphology, brain region, projection pattern, 
neurotransmitter, electrophysiological signatures and gene expression [8]. Identified 
categories of neurons overlap in various ways, and the prevailing definitions of neuron 
subtypes have constantly evolved as new concepts and technologies reshape thinking in 
the field. Therefore, there remain few well-established neuron subtypes. In fact, one of the 
top priority research areas proposed as part of the 2013 BRAIN initiative is to “identify 
and provide experimental access to the different brain cell types to determine their roles in 
health and disease” [9]. Thus, neuron classification remains an important topic in brain 
research. 
One of the clearest distinctions in neuronal cell types is between excitatory and 
inhibitory neurons. Excitatory neurons are those that upon firing of an action potential 
release neurotransmitters such as glutamate that activate post-synaptic neurons, increasing 
their likelihood to fire. In contrast, inhibitory neurons are those that release inhibitory 
neurotransmitters, such as gamma-aminobutyric acid (GABA), and decrease the likelihood 
of post-synaptic cell firing. In the mammalian cortex, excitatory principal neurons (also 
called “pyramidal” neurons due to their morphology) make up approximately 80% of the 
neuron population, while inhibitory or “interneurons” constitute the remaining 20% [10]. 
Although they make up a minority of the neuron population, interneurons play essential 
roles in regulating and synchronizing the activity of principal excitatory neurons [11-13]. 
It is therefore not surprising that interneuron dysfunction is implicated in many brain 




further cell subtypes can be subdivided in many ways.  
Since the dawn of the genomics age, cell classification has come to be increasingly 
defined on the basis of genetic signatures, which presumably give rise to functional 
properties [8]. In fact, the concept of a neuronal cell type has become synonymous with a 
group of cell that share distinct gene expression patterns which dictate their common 
functional properties [17]. The simplest approach to genetic neuron identification uses the 
expression of one specific marker gene to define a cell type. This approach has been widely 
adopted because it enables straightforward genetic access to specific cell types so that they 
can be labelled or manipulated in vivo (see “Genetically Encoded Neurotechnologies”), 
through exploitation of the natural promoter element for the marker gene. However, there 
are several limitations of this approach that are being brought to light.  First, although 
marker genes are correlated to neuron subtypes, their functions are only loosely related to 
those of the cell type they are used to denote.  For example, the alpha subunit of 
calcium/calmodulin dependent protein kinase II (CamKIIα) is a commonly used marker 
gene for excitatory pyramidal cells in the mammalian cortex [18-20], however its function 
is related to long-term potentiation, which is not specific to excitatory neurons [21-23]. 
This begs the question of whether these markers indeed label the cells we expect them to, 
and whether there are more functionally relevant biomarkers available.  
Furthermore, technological advancements in the field of genomics continually 
reveal new levels of complexity in the genetic diversity among neurons that express a 
common marker gene, including those directly linked to cell function. For example, 




inhibitory neurons, but significant level of heterogeneity has been noted within GAD 
interneurons [10, 24-26].  Continued efforts to clarify interneuron subtypes have focused 
on identifying a second level of marker genes that selectively label non-overlapping 
functionally distinct subsets of GAD+ cells [27, 28]. For example, calcium binding proteins 
such as parvalbumin (PV), calretinin (CR) and calbindin (CB), or neuropeptides such as 
somatostatin (SST), vasopressin (VIP) or neuropeptide Y (NPY) have all been shown to 
label subsets of interneurons [10]. However, these secondary markers exhibit varying 
levels of overlap [10, 24]. Thus, groups have recently employed single-cell sequencing 
techniques to even further delineate transcriptionally defined cell types that represent the 
intersections between marker gene populations [25, 26].  
One of the prevailing conceptual issues in the classification of neuron subtypes (and 
cell types in general) is how specific the distinctions between cell types should be. On one 
hand, high-level distinctions based on easily recognizable features (for example 
morphology) are proving to be too broad to facilitate detailed characterization of brain 
mechanisms [8]. On the other hand, single-cell genomics techniques continually reveal 
greater levels of diversity and heterogeneity among neurons, suggesting even that each 
individual cell is unique [25, 26]. Thus, the number of neuron classes can be arbitrarily 
large depending on the level of hierarchy one choses to examine, and the nature of the 
relationship between neuron identity and gene expression a topic of continual debate [29]. 
In the future, the field may settle upon fixed definitions of neuron subtypes, however, in 
order to reach that point we must continue to explore both the level of specificity needed 




A related challenge in neuroscience research is genetic targeting of specific cell 
types in vivo. Due to the continual refinement of neuron subtype definitions, there is an 
iterative, chicken-and-egg relationship between neural classification and gene targeting. 
We need methods of targeting known subtypes of neurons in order to facilitate the delivery 
of genetically encoded neurotechnologies for studies of brain function and disease 
mechanisms. At the same time, the results of many of these studies point to the fact neural 
cell types are highly heterogeneous populations, warranting further sub-classification 
(which then necessitates more refined targeting methods). Therefore, during the ongoing 
debate surrounding neural classification, the methods of gene targeting the in brain must 
also be constantly refined.  
 
1.2 Genetically Encoded Neurotechnologies 
 Genetically encoded neurotechnologies (GENs) are proteins that serve as sensors 
or actuators for neuronal cell processes. The first example of such a tool was the 
development of green fluorescent protein (GFP), which allowed the visualization of gene 
expression and protein localization within neurons in living organisms [30, 31]. Since the 
initial development of GFP, a wide spectrum of fluorescent proteins has been engineered 
as genetic reporters [32, 33]. When used in different contexts and combinations, these tools 
have enabled innumerable insights into neural physiology and brain function, such that the 
impact of fluorescent proteins in neuroscience research (and truly all biological research) 
cannot be overstated. One particularly impactful example is the combinatorial expression 




unique colors (a process that has come to be known as “brainbow”) [3]. This has enabled 
neuronal connectivity mapping [34-36] and cell lineage tracing during development [37-
39]. While fluorescent proteins themselves have been immensely valuable for neuroscience 
research, they have also served as the basis for other GENs.   
Genetically encoded optical neuron activity sensors have been engineered by 
linking fluorescent proteins to various ion-responsive protein domains, in order to read out 
calcium signals [40-43], membrane potential [44-48] or synaptic transmission [49-52]. 
Each approach to sensing neuronal activity has its advantages and disadvantages, however 
genetically encoded calcium indicators (GECIs) are currently the most widely adopted 
[53]. GECIs function based upon the fact that action potential firing leads to an influx in 
intracellular Ca2+, and thus changes in free Ca2+ can be used as a reliable surrogate measure 
for neural activity [54]. For example, “GCaMP” calcium sensors consist of circularly 
permuted EGFP fused to the M13 calcium binding domain of calmodulin, which results in 
a burst of green fluorescence upon calcium influx during an action potential [43]. GECIs 
have been implemented to facilitate insights into many aspects of brain function, including 
learning, memory and neural circuit evolution in awake, behaving animals [55-57]. 
Furthermore, recent advances in molecular engineering have resulted in improved, 
ultrasensitive GECIs [43] that have further expanded the application of in vivo calcium 
imaging, with GCaMP6f in particular becoming widely adopted due to its fast dynamics 
and high signal-to-noise ratio (SNR).  
In addition to sensors, which allow the visualization of neuronal gene expression 




chemogenetic [60, 61] biomolecules allow neural activity to be induced or repressed. 
Optogenetic actuator molecules are microbial rhodopsins, light-gated, transmembrane ion 
channels that have been adapted from microorganisms such as algae and archaebacteria. 
The expression of rhodopsins in genetically defined neural subtypes allows highly 
spatiotemporally precise neural manipulation upon laser light stimulation [62]. Since the 
early 2000s, this technique (termed “optogenetics”) has allowed innumerable insights 
across a broad range of neuroscience research areas – for example in the causal role of 
defined cell types in behavior [63-66] and the transmission of primary sensory information 
[67-69]. Since the initial implementation of optogenetics, a vast toolbox of optogenetic 
actuators has been engineered [4]. In particular, there has been much focus on the 
development of spectrally shifted rhodopsins [70, 71] to facilitate the simultaneous 
manipulation of multiple neuron types using different wavelengths of light. The impact of 
genetically encoded actuators in neuroscience research has already proven profound, and 
the possibilities continue to grow as increasingly complex combinatorial application of 
rhodopsins becomes possible.  
Overall, GENs vastly expand our abilities to probe and modify neurons in vivo, and 
are being used to reshape our understanding of brain function, behavior and disease. One 
of the greatest advantages of genetically encoded neurotechnologies lies in their ability to 
be chronically expressed in genetically defined neural subsets in the living brain  [72]. 
Therefore, harnessing the true power of these tools requires more advanced methods of 





1.3 Viral Gene Targeting in the Brain 
 There are two aspects of gene delivery which ultimately define the population of 
labelled cells: the physical DNA delivery method used and the gene expression system (or 
genetic classifier). The DNA delivery method dictates which cells receive the genetic 
classifier, and how it enters those cells. Elements of the researcher-designed genetic 
classifier then determine which of the cells that have received the DNA go on to express 
the transgene.  
While there are a wide variety of physical, chemical and biological DNA delivery 
methods available for biomedical research, only a limited number work robustly in the 
brain due to the challenges of bypassing the blood-brain barrier and transducing post-
mitotic neuronal cells [73]. Whole animal transgenic lines can provide invaluable gene 
targeting resources for neuroscience research [74-76], however they are costly and 
laborious to maintain and have only been largely successful in mice [29].  
Outside of transgenic methods, viral techniques provide the best efficacy for DNA 
delivery in the brain, as non-viral methods tend to be inefficient in transducing post mitotic 
cells [73, 77]. Viral gene delivery has many advantages, including reduced cost and time 
relative to transgenic techniques, and anatomical restriction of transgene expression to the 
locally injected brain region. Viral vectors can be combined with transgenic models to 
expand their utility (for example in two-component, recombinase-based expression 
systems), but more importantly can be used independently of transgenic targeting, for 
example in wild type animals or disease models. Thus, advancements in viral gene delivery 




rats) and human disease models (including mice).   
Genetic classifiers work orthogonally to DNA delivery methods, encoding the 
information to guide endogenous machinery within the appropriate subpopulation of the 
cells to express the transgene. Researcher-designed genetic classifiers, are intended to 
restrict transgene expression to a user-defined subpopulation of cells [29]. As previously 
discussed, one of the most common approaches to defining neuron subtypes is on the basis 
of marker gene expression. Accordingly, most genetic classifiers used in the brain rely 
upon cell-type specific transcriptional promoters taken from these marker genes to achieve 
targeting specificity. They can also include other regulatory elements such as enhancer or 
repressor sequences, or recombinase sites.  
There are several challenges to developing genetic classifiers for viral gene delivery 
in the brain, including the limited packaging capacities characteristic of the most reliable 
and widely used gene therapy vectors – lentivirus (LV) and adeno-associated virus (AAV) 
[77, 78]. Consequently, there are usually complications effectively packaging large cell-
type-specific promoters in these viruses. Several techniques have been used in attempts to 
overcome the limitation of LV and AAV vector packaging capacity for cell-type specific 
targeting in the mammalian CNS.  
One major strategy has been to utilize short gene regulation elements. For example, 
short or shortened versions of naturally occurring promoters for cell-type-specific marker 
genes have been employed with varying success. The neuron-specific human Synapsin 
(hSyn) promoter is naturally short (~480 bp) and is thus commonly employed in viral 




and glia). Similarly, a 1.3 kb fragment of the mouse CamKIIα promoter is commonly used 
to label excitatory neurons [18]. Other attempts to use shortened promoters in viral vectors 
have met with variable success. For example, Nathanson et al found that shortened 
mammalian promoters for PV and SST (markers for specific subsets of inhibitory neurons) 
did not confer the expected cell-type specific labelling [80]. For many neuron types it has 
not been possible to engineer a shortened promoter element with sufficient specificity. 
Another related strategy is the use of short, cell-type specific enhancer elements upstream 
of a minimal promoter. For example, short Dlx enhancer elements taken from the distalless 
homeobox genes that are known to express in developing interneurons have also been used 
to label inhibitory neurons in the adult mammalian brain using AAVs [81-83].  
Additionally, viral pseudotyping has also been used to help bias transduction 
toward specific cell types. Pseudotyping refers to the practice of packaging a viral genome 
inside an alternative envelope or capsid protein.  There are a handful of coat envelope 
proteins available for pseudotyping LV (including VSVG, Ebola, Mokola, LCMV and 
MuLV envelopes)[84]. Vesicular stomatitis virus glycoprotein (VSVG) -pseudotyped LV 
is commonly used for transducing central nervous system cells due to its ability to confer 
stable, long-term expression [18, 85], and it also has been shown to exhibits an infection 
bias toward excitatory neurons in the mouse brain [86].  Furthermore, there have been 
eleven serotypes of AAV discovered, each with a different capsid protein that has a 
different tissue and/or cell type transduction bias [86-89]. AAV serotype 1 (recombinant 
AAV using AAV-2 genome vector, pseudotyped with AAV-1 capsid protein) exhibits a 




recently, a systematic comparison of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain 
demonstrated that AAV serotype 9 is the most efficient serotype for transducing cortical 
neurons, with slight tropism towards cortical inhibitory neurons [88]. While viral 
pseudotyping can help bias gene delivery, used alone it is not a means of achieving highly 
specific neuron subtype targeting.   
Both physical DNA delivery method and genetic classifier design contribute to the 
success of cell-type specific gene targeting. In the brain, viral gene delivery is one of only 
efficient physical vehicles for DNA delivery to post-mitotic neurons, especially in 
genetically intractable species and animal models of human disease. However, the limited 
DNA packaging capacity of the safest and most widely used viral vectors places restraints 
on the design of virally delivered genetic classifiers. Several approaches using short genetic 
elements or viral pseudotyping have been used in attempts to overcome this limitation. 
However, there remains a need for viral gene targeting strategies that confer high 
specificity, in a multiplexed manner, and across a variety of animal models.  
 
1.4 MicroRNA-Based, Viral Cell Type Labelling 
MiRNAs are small (~22 nt), endogenous, noncoding RNAs. They function in post-
transcriptional gene regulation by binding to complementary recognition sequences in 
mRNAs, resulting in gene inhibition via RISC-complex mediated transcript degradation or 
stalled translation. Individual miRNAs regulate networks of related genes, and many have 
distinct developmental, tissue-, lineage- and cell-type specific expression patterns [90-92] 




miRNAs provide an excellent framework for defining and labelling specific cell types, and 
due to their small size, recognition sites can be easily integrated into viral vectors.  
Over the past decade, researchers have begun to exploit endogenous microRNA 
regulation in order to control the expression of virally delivered transgenes [95]. This 
entails the incorporation of specific miRNA binding sites within the expression cassette so 
that the resulting transcript becomes susceptible to silencing in cells expressing the specific 
miRNA. Early in vivo applications of this technique included silencing off-target 
expression of a virally delivered genes on the basis of tissue [96-100], lineage [90], 
differentiation state [96, 101], or tumor state [102], with much focus on addressing liver 
toxicity and cancer cell specificity for therapeutic oncolytic viruses. Within the central 
nervous system, miRNA-based viral transgene targeting has been used to preferentially 
label astrocytes in the mouse hippocampus, striatum and cerebellum [103] and to label 
retinal pigment epithelium or photoreceptors in the mouse and pig retina using AAV [104]. 
Importantly, miRNA-based delivery vectors do not detectably disturb endogenous miRNA 
expression or the regulation of natural targets [96].  
One of the major limitations of miRNA-based targeting is the fact that miRNAs are 
an inhibitory gene regulation mechanism, and function by knocking down expression in 
off-target cells rather than inducing expression in target cells. Thus, these early applications 
involve the use of a single miRNA sequence to silence gene expression in a particular tissue 
type or cell lineage. However, further specification of target cell subtype using 
combinations of miRNAs to silence expression in multiple off-target populations was not 




are needed for on vs. off-target cells to design such vectors, and while many tissue-specific 
miRNA profiles were reported [105-107], cell-type specific miRNA profiles were not 
available until more recently. In 2012, He et al reported the first neuron-type specific 
miRNA profiles [92], enabling miRNA-based targeting in the brain for the first time.  
Given previous demonstrations, it was easy to surmise that miRNA-based viral 
gene targeting could provide a useful strategy for neuron type classification and targeting 
in the brain.  In addition to the small size of miRNA recognition sites which facilitates viral 
packaging, there are several other properties of miRNAs that make them a suitable 
framework for delineating neuron subtypes. First, miRNA expression is highly enriched in 
the mammalian brain compared to other organs [105-107], which makes them an 
appropriate regulatory mechanism to exploit for neuroscience applications.  Furthermore, 
several miRNAs and/or multiple recognition sites for one miRNA can act to regulate the 
expression of a single gene. Thus, in theory combinations of miRNA sites could be 
engineered to finely tune targeting specificity to cell subtypes, including the many neuron 
types in the brain for which no cell-type-specific promoters have been identified. This 
dissertation describes the first demonstration of neuron-subtype specific, miRNA-based 
viral transgene targeting. For simplicity, these vectors are called miRNA-guided neuron 





CHAPTER 2 – RATIONALLY DESIGNED MICRORNA-BASED GENETIC 
CLASSIFIERS TARGET SPECIFIC NEURONS IN THE BRAIN 
 
Reprinted (adapted) with permission from (“Rationally Designed MicroRNA-
Based Genetic Classifiers Target Specific Neurons in the Brain” Marianna K. Sayeg, 
Benjamin H. Weinberg, Susie S. Cha, Michael Goodloe, Wilson W. Wong, and Xue Han. 
ACS Synthetic Biology 2015 4(7), 788-795. DOI: 10.1021/acssybio.5b00040). Copyright 
2015 American Chemical Society.  
 
2.1 Abstract 
Targeting transgene expression to specific cell types in vivo has proven 
instrumental in characterizing the functional role of defined cell populations. Genetic 
classifiers, synthetic transgene constructs designed to restrict expression to particular 
classes of cells, commonly rely on transcriptional promoters to define cellular specificity. 
However, the large size of many natural promoters complicates their use in viral vectors, 
an important mode of transgene delivery in the brain and in human gene therapy.  Here, we 
expanded upon an emerging classifier platform, orthogonal to promoter-based strategies, 
that exploits endogenous microRNA regulation to target gene expression. Such classifiers 
have been extensively explored in other tissues, however their use in the nervous system 
has thus far been limited to targeting gene expression to neurons rather than supporting 
cells. Here, we tested the possibility of using combinatory microRNA regulation to specify 
gene targeting between neuronal subtypes, and successfully targeted inhibitory cells in the 








The ability to genetically modify specific cell types is essential in defining their 
contributions to physiological systems, such as the functional role of neural subsets in brain 
computation and behavior. Genetic classifiers are synthetic gene expression systems 
designed to restrict transgene expression to particular classes of cells, to facilitate cell-type 
characterization. Most commonly, they rely upon transcriptional promoters with tissue-
restricted expression patterns to define cellular specificity. It has been challenging to 
develop genetic classifiers for use in the brain, due to the limitations of current gene 
delivery methods and complications recapitulating natural promoters. While whole animal 
transgenic techniques have provided invaluable resources for targeting gene expression to 
specific cells, viral gene delivery remains an important technique to further expand the 
utility of transgenic models [108], to target gene expression in genetically intractable 
species, and to advance human gene therapy. Viral techniques are particularly important in 
the brain because non-viral methods tend to be inefficient in transducing post-mitotic cells 
such as neurons.  
One major challenge facing viral gene delivery is the limited DNA packaging 
capacity characteristic of the most reliable and widely used gene therapy vectors, lentivirus 
and adeno-associated virus (AAV) [109]. Consequently, there are usually complications 
effectively packaging large cell-type-specific promoters in these viruses. Some shortened 




however for many cell types it is difficult to identify a short promoter element with 
sufficient specificity [80]. Viral pseudotyping has been explored as a supplemental means 
of increasing targeting specificity [111], however envelope protein choices are limited, and 
modifications are often difficult to engineer while maintaining virus stability. Here we 
explored an alternative classifier platform, ideally suited for viral delivery, which exploits 
endogenous microRNA (miRNA) regulation to target gene expression to specific neuron 
subtypes in the living brain.   
miRNAs are small (~20 nt), non-coding RNAs that inhibit gene expression by 
hybridizing to complementary recognition sites within mRNA transcripts, leading to 
repressed translation or direct degradation of their gene targets. A given miRNA tends to 
regulate sets of related genes, and its expression is usually correlated to that of its 
downstream targets [112].  Genetic classifiers incorporating miRNA recognition sites have 
been demonstrated extensively in cell culture [113, 114]. Because miRNA recognition sites 
are small, they can be easily integrated into viral vectors, and viral miRNA-based 
classifiers have started to emerge for select applications in vivo, including improving gene 
expression targeting in the liver and spleen, and restricting stem cell therapies to the tumor 
microenvironment [115]. Within the nervous system, microRNA-based classifiers have 
shown potential in restricting transgene expression to astrocytes [103] or photoreceptors 
[104]. 
In light of the recent characterization of neuron-type and brain-region specific 
miRNA profiles in mice [92], we hypothesized that miRNA-based classifiers could be 




cells, but between neural subtypes. To explore this principle, we designed several virally 
deliverable, neuron-type specific, miRNA-based classifiers (for simplicity, miRNA-guided 
neuron tags: mAGNETs), and tested the combinatory effects of different miRNAs in 
targeting a known cell type, cortical inhibitory neurons. The size (> 9 kb) and complexity 
of the natural inhibitory-neuron-specific (GABA) promoter makes it essentially impossible 
to package in high-titer lentivirus or AAV, and much effort has been directed toward 
targeting these neurons using shortened promoters [116]. Here, we were able to achieve 
inhibitory-neuron-specific targeting using signature miRNAs that selectively inhibit 
expression in excitatory cells and spare expression in the targeted inhibitory cells. The 
presented mAGNETs demonstrate the feasibility of rationally designing neuron-type-
specific classifiers driven entirely by miRNA regulation, completely orthogonal to 
promoter- or serotype-based gene targeting strategies. 
  
2.3 Results 
2.3.1 Selection of signature microRNAs for mAGNET neuron subtype targeting 
To test the feasibility of using miRNA regulation to target neural subtypes, we 
designed several mAGNET classifiers specific to cortical inhibitory neurons. Because 
miRNA regulation is inhibitory, we analyzed the cell-type and brain-region-specific 
miRNA expression profiles reported by He et al seeking signature miRNAs strongly 
associated with excitatory neurons. We identified three signature miRNAs, miR-128, miR-
221, and miR-222, which exhibited at least 1000 deep sequencing raw reads and had the 




mouse cortex (see Table 2). We then designed several mAGNET constructs containing 
cassettes of recognition sites for two or three of these signature miRNAs (see Figure 1a). 
The classifiers were built in lentiviral vectors containing a constitutive, non-specific EF1α 
promoter driving the expression of an EGFP reporter gene, with miRNA recognition 
cassettes positioned within the 3’ UTR. We used an equivalent EGFP-only vector, without 
any miRNA recognition sites, as a control (see Figure 1a).  
To test our classifiers in the brain, we produced high-titer lentiviruses of each 
mAGNET and the EGFP control, and injected them into adult mice at two locations in the 
cortex (see Figure 1b). For all constructs (see Figure 1a) and conditions (two weeks vs. 
four weeks post-injection) tested, n = 2 mice were examined. To quantify cell type 
preference resulting from either the EF1α promoter or lentivirus tropism, we first analyzed 
EGFP expression patterns in mice injected with the control virus. We analyzed the 
colocalization patterns of EGFP+ cells with an inhibitory neuron marker (GABA), an 
excitatory neuron marker (CamKII), and a glial cell marker (GFAP). In the cortex at two 
weeks post-injection, we found that approximately 13% of EGFP+ cells expressed GABA, 
85% expressed CamKII, and 4% expressed GFAP (see Figure 1c and Table1, 71 cells 
analyzed for GFAP staining). Note that immunohistochemistry for each marker was carried 
out on separate brain slices. These results confirm that our lentivirus with an EF1α 
promoter infects primarily neurons (labeled only about 4% GFAP+ glia cells). Also, the 
observed 85% colocalization with CamKII is consistent with the distribution of excitatory 
to inhibitory neurons in the mouse cortex (approximately 80:20) [117], with a slight 





Figure 1. mAGNET design and experimental setup.  
(a) EGFP control and mAGNET lentiviral construct designs with miRNA recognition sites, Long Terminal 
Repeats (LTR) and the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE). (b) 
Cortical injection sites in the mouse brain – motor cortex (1): +1.000 mm ML, +1.800 mm AP, -1.250 mm 
DV, parietal cortex (2): +1.000 mm ML, -1.500 mm AP, -0.900 mm DV. (c) Representative confocal 
images of EGFP fluorescence from cortical cells expressing the EGFP control, α-GABA, α-CAMKII, or α-
GFAP immunofluorescence, and colocalization. Scale bars 40 μm. Arrowheads indicate examples of EGFP 
colocalization with immunofluorescence. (d) Comparison of viral transduction at motor cortex (1) sites 
across mice infected with the EGFP control or one of the mAGNET constructs. Scale bars 150 μm. 
 
When we performed immunohistological analysis in mice infected with lentivirus-
packaged mAGNETs, we noticed that EGFP+ cells were sparsely distributed within 
cortical injection sites compared to observations in EGFP control animals (see Figure 1d). 
The overall spread of EGFP+ cells appears similar in mice infected with the EGFP control 




although mAGNET-labeled GFP+ cells are much more sparsely distributed. EGFP+ cells 
were clearly visible without any immunostaining and exhibit no observable difference in 
fluorescence intensity across mice, suggesting that the inclusion of miRNA recognition 
cassettes led to selective reduction of EGFP expression in some cells, but not all cells. 
Together, these results demonstrate that inclusion of multiple miRNA binding sites within 
mAGNETs did not interfere with lentivirus packaging, which is sensitive to repetitive DNA 
sequences, and that mAGNETs targeted EGFP fluorescence to a sparsely distributed 
population of neurons. 
We next further examined the mAGNETs’ targeting specificities between 
excitatory and inhibitory neurons. When designing our mAGNETs, we noted that the 
expression level of candidate signature miRNAs varied drastically. For example, the raw 
sequencing reads for miR-128 and miR-222 span four orders of magnitude (see Table 2), 
suggesting that they might differ in transgene inhibition efficiency. We designed the first 
two mAGNET constructs to test the expression threshold for consideration as a signature 
miRNA. The 4X2C mAGNET contains recognition cassettes for the two signature 
miRNAs with the highest raw reads, miR-128 and miR-221, whereas the 4X3C mAGNET 
contains cassettes for all three (see Figure 1a). At two weeks post-injection, we found that 
of the cortical EGFP+ cells transduced by either 4X mAGNET, ~70% expressed GABA, 
and ~24% expressed CamKII (see Figure 2a&b, Figure 3b and Table 1). This result 
suggests that miR-222 does not contribute to mAGNET-mediated EGFP knockdown, and 
thus the expression threshold for consideration as a signature miRNA in this case is greater 




expression threshold is a critical consideration for such classifier designs. The absolute 
threshold for a given application should probably be determined on a case-by-case basis, 
as it relies upon the strength of the promoter used in the viral vector, the ratio of miRNA 
expression in the target and off-target cells, the number of miRNA recognition site repeats, 
as well as other translation regulation factors.  
 
 
Figure 2. mAGNETs preferentially target cortical inhibitory neurons.  
Representative confocal images from cortical injection sites, of EGFP fluorescence from cells expressing 
the 4X2C (a&c), 4X3C (b&d), 8X2C (e), or 12X1C (f) mAGNET, α-GABA and/or α-CAMKII 
immunofluorescence, and colocalization. Scale bars: 40 μm. Arrowheads indicate examples of EGFP 
colocalization with immunofluorescence. (c&d) Mice sacrificed and immunohistochemistry performed at 




2.3.2 Temporal dynamics of mAGNET classifier targeting specificity 
To analyze the temporal dynamics of classifier specificity, we examined cells 
transduced by both 4X mAGNETs at four weeks post-injection, and found that GABA and 
CamKII colocalization remained the same for both mAGNETs (~71% of EGFP+ cells were 
GABA+, 191 and 158 cells for the 4X2C and 4X3C mAGNET respectively) (see Figure 2 
c&d) compared to that observed at two weeks post-injection. This suggests again that miR-
222 does not contribute to mAGNET-mediated EGFP knock down and that expression of 
the other signature miRNAs does not vary significantly over time. The temporal stability 
of mAGNET targeting suggests that these signature miRNAs may be associated with 
constitutive pathways in excitatory cells that require constant regulation. In fact, it was 
recently discovered that miR-128 is an essential regulator of neuronal excitability [118].  
We next tried to improve inhibitory neuron targeting by increasing the number of 
recognition sites for the two efficacious miRNAs. We designed one mAGNET with eight 
identical recognition sites for both miR-128 and miR-221, and another with twelve 
identical recognition sites for miR-128 only (8X2C and 12X1C mAGNETs, Figure 1a). 
The 12X1C mAGNET-targeted EGFP expression exhibited 72-73% colocalization with 
GABA+ inhibitory neurons in the cortex (see Figure 2f, 3b and Table 1), nearly identical 
to that achieved with the 4X2C and 4X3C classifiers. The 8X2C mAGNET, on the other 
hand, exhibited an increased specificity towards cortical inhibitory neurons, presenting 80-
83% colocalization with GABA (Figure 2e, 3b and Table 1). This level of specificity is 
considerable, given that inhibitory cells make up only 20% of cortical neurons and 




multiplying the sites for one miRNA has only a small effect on repression[119], and further 
suggest that the synergistic effects of several signature miRNAs can be tuned to improve 
specificity.  
To further verify the identity of the inhibitory cell population targeted by the 8X2C 
mAGNET, we analyzed the colocalization of EGFP+ cells with α-parvalbumin (PV) and 
α-somatostatin (SST) (Figure 5), and found that 30% are PV+ (n=57 cells), and 51% are 
SST+ (n=54 cells). Although identical expression levels of miR-128 and miR-221 in PV+  
 
 
Figure 3. mAGNET targeting is brain-region specific.  
(a) Hippocampal injection site in the mouse brain – hippocampus (3): +1.000 mm ML, -1.500 mm AP, -
1.750 mm DV. (b) Quantification of EGFP fluorescence colocalization with α-GABA or α-CamKII 
immunofluorescence at two weeks post-injection (n=2 mice each design). Cortex data is pooled across both 
cortical injection sites. *** p < 0.0005, or ns (no significance) Pearson’s Chi Squared Test (see 
Supplemental Materials). (c-d) Representative confocal images from hippocampal injection site of EGFP 
fluorescence from cells expressing the EGFP control (c) or 8X2C mAGNET (c), α-GABA and α-CAMKII 
immunofluorescence, and colocalization. Scale bars: 40 μm. Arrowheads indicate examples of EGFP 




and SST+ neurons were reported by He et al, miRNA activity may differ amongst 
inhibitory cell types within different cortical depth or layers. This suggests that with 
optimization, it may be possible to target specific subtypes of inhibitory neurons with 
mAGNET classifiers, a task that has proven difficult with shortened promoters.   
2.3.3 mAGNET gene targeting is brain-region specific 
Because our classifiers were designed based on cortical miRNA profiles, and 
miRNA expression has been shown to vary between brain regions [120], we further 
examined the targeting specificity at a site distant from the cortex. Each mouse also 
received an additional lentivirus injection in the hippocampus (see Figure 3a), where cell-
type-specific miRNA profiles are yet to be determined. We found that of the hippocampal 
EGFP+ cells transduced by any of the mAGNETs, <20% are inhibitory neurons (GABA+) 
and >80% are excitatory neurons (CamKII+), identical to results achieved with the EGFP 
control construct (see Figure 3b-d, Figure 6 and Table 1). This indicates that miR-128 and 
miR-222 are not differentially expressed at high enough levels to bias mAGNET 
expression in hippocampal neurons. Tan et al recently demonstrated that miR-128 governs 
the expression of ion channels relevant for motor control, and is several fold more prevalent 
in the cortex than in the hippocampus. It is probable that the lower expression level of miR-
128 in hippocampus as well as the additive knockdown by miR-222 is driving the cortex-
specific inhibitory neuron targeting observed here. For all mAGNETs, inhibitory neuron 
targeting preference was consistent at the two cortical testing locations and across mice 
(see Figure 3b and Table 1), and there was no significant targeting effect in the 




classifiers achieved brain-region specific targeting.  
 
Table 1. mAGNET selectivity across brain areas 
 
aPercentages of GFP+ cells colocalized with α - GABA or α - CamKII for each construct by injection site, 
numbers in parentheses indicate the number of GFP+ cells analyzed. *** p < 0.0005 Pearson’s Chi Squared 
Test (see Supporting Information).  
 
2.3.4 mAGNETs do not disturb normal neural physiology 
Finally, to test the possibility that miRNA-based classifiers might sequester 
miRNAs away from endogenous targets and affect cell phenotype, we characterized 
electrophysiological properties of neuron cultures transfected with one of our mAGNETs. 
After confirming a 98% co-transfection rate with calcium phosphate (n=295 neurons 
examined), we inferred the identities of neurons co-transfected with the 4X2C mAGNET 
and a CamKII_mRuby2 excitatory cell labelling construct (see Figure 7a) as follows: 
EGFP+ only cells are inhibitory neurons that do not express CamKII, mRuby2+ only cells 
are CamKII-expressing excitatory neurons with miRNA-mediated EGFP repression, and 
EGFP+/mRuby2+ cells are CamKII-expressing excitatory neurons without miRNA-
mediated EGFP repression (Figure 4a). We then recorded membrane currents using patch 
clamp recordings from neurons co-transfected with 4X2C mAGNET and CamKII-
mRuby2, and those co-transfected with EGFP control and CamKII-mRuby2 (Figure 
7c&d). Current-voltage profiles (Figure 4b&c) from neurons with various expression 
Injection Site Marker Controla 4X2Ca 4X3Ca 8X2Ca 12X1Ca 
Cortex (1) 
α - GABA 14% (123) 70%*** (53) 69%*** (68) 83%*** (112) 72%*** (104) 
α - CamKII 86% (144) 24%*** (97) 23%*** (90) 15%*** (117) 23%*** (103) 
Cortex (2)  
α - GABA 13% (105) 72%*** (87) 72%*** (53) 80%*** (54) 73%*** (55) 
α - CamKII 85% (110) 24%*** (62) 31%*** (55) 16%*** (55) 17%*** (63) 
Hippocampus (3) 
α - GABA 14% (121) 18% (71) 15% (103) 15% (120) 16% (76) 




profiles showed no significant differences, indicating that mAGNET-mediated EGFP 
knockdown by endogenous miRNAs does not cause a significant change in 
electrophysiological properties measured here. Notably, we found that 4X2C mAGNET 
achieved a cortical inhibitory neuron targeting specificity of only 25% in vitro, (Figure 7b), 
in sharp contrast to the ~71% achieved in vivo (Table 1). This discrepancy indicates that 
neurons in culture have drastically different miRNA expression profiles than neurons in 
the brain, probably due to the traumatic conditions required to separate them from their 
natural niche, and the extreme changes in the chemical and mechanical properties of their 
environment. Thus, while in vitro neuron cultures represent an attractive larger-scale 
screening platform, it is preferable to optimize mAGNETs directly in vivo. 
With further improvements, another interesting use for the presented mAGNET 
classifiers would be to selectively target and characterize the fraction of CamKII cells 
without repression, as they may constitute a novel subset of excitatory cells with different 
excitability. While it is desirable to maintain stable transgene expression levels for cell-
type targeting applications, for other applications, miRNA regulation could be exploited to 
dynamically regulate transgenes and monitor phenotype changes.  For example, classifiers 
based on highly variable signature miRNAs have been useful for monitoring neural stem 
cell differentiation [121]. In adult neurons, tools for monitoring phenotype changes, such 
as expression patterns of the transcription factor c-fos and the synthetic promoter E-SARE 
[122, 123], have been designed to broadly target cells with elevated activity patterns. Better 
understanding of the pathways regulated by individual miRNAs will enable forward-




wide range of specific phenotype changes in adult neurons. 
 
 
Figure 4. mAGNET regulation is not associated with electrophysiological changes.  
(a) Representative image showing mAGNET-transfected neurons expressing only EGFP (EGFP+), only 
mRuby2 (mRuby2+) or both EGFP and mRuby2 (EGFP+/mRuby2+). White arrows indicate exemplar cells 
of these three types. Scale bars 100 µm. (b) Representative voltage traces for a EGFP+/mRuby2+ 
mAGNET-transfected neuron, clamped at -80 to 10mV (bottom to top) at 10mV intervals. (c) Mean whole-
cell currents recorded in voltage clamp mode were plotted versus voltage. Error bars show mean ± standard 







Here we have demonstrated the feasibility of using mAGNET classifiers to target 
a specific desired subset of neurons in the living brain, cortical inhibitory neurons. 
mAGNETs represent a compact, tailorable genetic classifier platform for neuron-type and 
brain-region specific gene expression targeting. The primary advantage of this classifier 
platform is that small miRNA recognition sequences can be easily packaged and modularly 
combined on the same circuit to tailor specificity in viral vectors relevant for gene therapy 
in the brain. The ~82% targeting rate achieved using only two signature miRNAs 
demonstrates the potential of the mAGNET approach, although further optimization for 
greater specificity is desirable for many neuroscience applications. There are several 
avenues to continuing optimization, including altering the ratio and placement of miR-128 
and miR-222 sites, and exploring alternative signature miRNAs and promoters. The strong, 
constitutive EF1α promoter used here may be driving transcription at a faster rate than the 
gene regulation capability of the signature miRNAs. Using a weaker promoter such as a 
synapsin promoter may allow more efficient repression in excitatory cells.  
The main drawback of relying on miRNA regulation to target gene expression is its 
inhibitory nature – in order to “target” one cell type, signature miRNAs must be identified 
to exclude all other cell types. Greater knowledge of the regulatory functions and brain 
region specific expression profiles of individual miRNAs will facilitate more complex 
mAGNET designs. However, it is probably unnecessary to identify miRNAs to exclude all 
unwanted cell types in the given region. Here, we did not attempt to identify miRNA sites 




GFAP glial cell marker. Choosing at least one signature miRNA with both a relatively high 
expression across many cell types and a low ratio of expression in on-target cells compared 
to the most abundant off-target cell population(s) (miR-128 in this case) should provide a 
good starting point from which a mAGNET design can be optimized. Alternatively, 
miRNA-based targeting could be used in conjunction with traditional shortened promoter 
or Cre Recombinase strategies to enhance targeting specificity and reduce off-target 
effects, as has been demonstrated in other tissues [124]. Finally, it may be possible to use 
a mAGNET inverter circuit utilize positive signature miRNA markers to control targeting 
specificity [125].  
As the regulatory functions of individual miRNAs are further explored and 
quantitative models of miRNA regulation improve [126], such classifiers can be designed 
for many neuroscience applications. For example, mAGNETs would be useful for targeting 
other difficult cell types in vivo and in genetically intractable species, targeting optogenetic 
[127] neurotechnologies to precisely characterize novel cell types [128, 129], and 
monitoring dynamic phenotype changes in adult neurons. Finally, as individual miRNAs 
are becoming increasingly linked to different neurological and psychiatric diseases [130, 
131], mAGNETs could prove an effective platform for targeting gene therapies to diseased 
neuron populations. While the mAGNETs reported here represent a simple proof-of-
principle, elaboration and optimization of these neuron-type specific classifiers could have 






mAGNET Vector Construction. miRNA recognition sites were designed as the 
exact reverse complement of the identified signature mouse miRNAs. The designed 
miRNA recognition cassettes were positioned after GFP in a pHR-lentiviral transfer 
plasmid backbone (http://www.addgene.org/50839/) driven by an EF-1a promoter 
(http://www.ncbi.nlm.nih.gov/nuccore/HQ644134.1). Single-stranded DNA 
oligonucleotides containing the miRNA sites were synthetized by IDT DNA, annealed, and 
cloned into the NotI sites within the backbone through standard molecular cloning 
procedures (for sequences see Supporting Information).  
Lentivirus Production. Replication-incompetent lentivirus was packaged via 
triple transfections of pHR-4X2C_mAGNET, pHR-4X3C_mAGNET, pHR-
8X2C_mAGNET or pHR-12X1C_mAGNET lentiviral transfer plasmid (will be deposited 
to PubMed and Addgene), plasmid pMD2.G encoding for VSV-G pseudotyping coat 
protein (Addgene 12259) and pDelta 8.74 (Addgene 5682) helper packaging plasmid, into 
HEK293FT cells (Life Technologies, R700-07) using TransIT-293 transfection reagent 
(Mirus Bio LLC, MIR 2700), and then purified through ultra-centrifugation. Viral titer was 
estimated to be 10E9 particles/mL based on established tittering correlations between in 
vivo observations and in vitro HEK293FT infection. 
Stereotaxic Surgeries. All procedures were done in accordance with the National 
Institutes of Health Guide for Laboratory Animals and were approved by the Boston 
University Institutional Animal Care and Use and Biosafety Committees. We injected each 




cortex1 (+1.000 mm ML, +1.800 mm AP, -1.250 mm DV), cortex2 (+1.000 mm ML, -
1.500 mm AP, -0.900 mm DV) and hippocampus (+1.000 mm ML, -1.500 mm AP, -1.750 
mm DV). Two mice were injected per condition (n = 12 mice total). 1 µL lentivirus was 
injected per site.  
Immunohistochemistry. At two or four weeks post-injection, mice were sacrificed 
and perfused with 4% PFA. Brains were post-fixed in 4% PFA for two hours, flash froze 
in OCT, and then sectioned at 40 µm. Brian slices were stained with markers for GABA 
(Sigma, A2052), CamKII (Santa Cruz Biotech, sc-13082), GFAP (Millipore, AB5541), PV 
(Swant, PV25) or SST (Abcam, ab8904), followed by Alexafluor-568 goat-anti-rabbit or 
goat-anti-chicken secondary antibody and ToPRO-3 nuclear dye (Life Technologies).  
Confocal Imaging and Quantification. Confocal imaging was performed on an 
Olympus FV1000 scanning confocal microscope, using a 60X water immersion lens. Z-
stacks were taken by imaging at 2 μm intervals throughout the slices. EGFP+ cell bodies 
were identified by comparison with ToPRO-3 nuclear staining, then each identified EGFP+ 
cell was categorized as immunopositive or immunonegative for the antibody stain. Note 
that staining for each marker was performed on separate brain slices. We analyzed 1-4 non-
overlapping confocal stacks from each of 2-6 slices per injection site, per mouse. At least 
50 EGFP+ cells were analyzed per condition (see Pearson’s Chi Squared Test). All 
hippocampal images were taken of the CA1 cell layer. 
Pearson’s Chi Squared Test. The Pearson’s chi squared test statistic with one 
degree of freedom (since cells examined are either excitatory or inhibitory) was calculated 




number of counts for inhibitory/excitatory cells and the expected distribution of 20% 
inhibitory and 80% excitatory cells. A chi squared test of independence with one degree of 
freedom requires an expected frequency of at least 10 to produce reliable approximations, 
and since inhibitory cells make up approximately 20% of neurons in the cortex and 
hippocampus, 50 neurons in each test was determined to be the minimum sample size.  
Cortical Neuron Culture Transfection and Electrophysiology. All experiments 
were approved by Boston University Institutional Animal Care and Use Committee. 
Cortical neurons were harvested from CD-1 mice on postnatal day 0 or 1 as described 
previously[132]. Neuron cultures were transfected on day 5 with a combination of pHR-
CamKII_mRuby2 and either pHR-4X2C_mAGNET or pHR-EGFP_Control (1.5 µg per 
construct) via calcium phosphate transfection. Whole-cell voltage clamp recordings were 
performed on postnatal day 7 or 8 (n= 6-8 neurons per condition) with a Multiclamp 700A 
amplifier (Molecular Devices, LLC) controlled with pClamp 10 software (Molecular 
Devices, LLC). Cultured neurons were bathed in extracellular solutions that contained (in 
mM): 140 NaCl, 3 KCl, 2.5 CaCl2, 1.5 MgCl2, 10 HEPES, 11 glucose; (pH, 7.4, 305 
mOSM). Patch electrodes were pulled from thick-walled borosilicate glass capillaries with 
resistances of ~5 MΩ and filled with intracellular solution that contained (in mM): 130 K-
gluconate, 2 NaCl, 7 KCl 1 MgCl2, 1 EGTA, 10 HEPES, 2 ATP-Mg, 0.3 GTP-Tris; the 
(pH, 7.4; 290mOSM). All experiments were performed at room temperature. Neuron 
culture co-transfection rates were determined by transfecting day 5 cortical neurons with a 
combination of pHR-EGFP_Control and pHR-EF1α_mKate, and quantifying EGFP and 




2.6 Supporting Information 
2.6.1 Supporting Tables and Figures 
 
Table 2. Deep Sequencing Reads in Mouse Cortex [92] 
miRNA CK+* Cells Gad2+** Cells CK:Gad2 
 miR-128 1,533,834 91,187 16.8 
 miR-221 25,694 2,101 12.2 
 miR-222 7,259 768 9.5 
 
*CK, Calcium/calmodulin-dependent protein kinase II, excitatory neurons 




Figure 5. mAGNET cortical inhibitory neuron characterization.  
Representative confocal images from cortical injection sites of EGFP fluorescence from cells 
expressing the 8X2C mAGNET, α-PV and α-SST immunofluorescence, and colocalization. Scale 







Figure 6. mAGNET targeting selectivity in the hippocampus.  
(a-c) Representative confocal images from hippocampal injection site of EGFP fluorescence from 
cells expressing the 4X2C (a), 4X3C (b), or 12X1C (c) mAGNET, α-GABA and α-CAMKII 
immunofluorescence, and colocalization. Scale bars: 40 μm. Arrowheads indicate examples of EGFP 






Figure 7. Cortical neuron expression profiles in cultured neurons in vitro.  
(a&c) Pairs of constructs co-transfected into mouse cortical neuron cultures. (b) Percentage of 
cultured neurons co- transfected as indicated in (a) expressing EGFP alone (EGFP+), mRuby2 alone 
(mRuby2+) and both EGFP and mRuby2 (EGFP+/mRuby2+) observed at 24 hours and 96 hours post-
transfection (n = 130 cells examined at 24h, and n=108 cells at 96h). (d) Percentage of cultured 
neurons with the three indicated expression profiles co-transfected with control vectors indicated in 
(c), at 24 hours and 96 hours post-transfection (n = 102 cells at 24h, 157 cells at 96h).  
 
 













































CHAPTER 3 – A MICRORNA-BASED GENE TARGETING TOOL FOR 
VIRALLY LABELLING INTERNEURONS IN THE RODENT CORTEX 
 
3.1 Abstract 
More specific and broadly applicable viral gene delivery methods for labelling 
neuronal subtypes are desired, especially in genetically intractable species and in rodent 
transgenic disease models. Here, we develop a viral vector that restricts transgene 
expression to GABAergic interneurons in the rodent neocortex by exploiting endogenous 
microRNA regulation. Our interneuron-targeting, microRNA-guided neuron tag, “GABA-
mAGNET”, achieves >95% interneuron selective labelling in the mouse cortex, including 
in a murine model of autism, and some preferential labeling of interneurons in the rat brain. 
We demonstrate the use of our GABA-mAGNET by performing simultaneous, in vivo 
optogenetic control of two distinct neural subtypes. This novel interneuron labelling tool 




A wide variety of genetically encoded sensors and actuators [30, 40, 44, 49, 58, 60, 
133] are revolutionizing our ability to observe and modify gene expression and neural 
activity in the brain. However, harnessing the full potential of these tools and advancing 
our understanding of brain function requires more selective and broadly applicable 
methods of restricting gene expression to specific neuron subsets. Whole animal transgenic 




to mice [74, 75] and non-vertebrate animals [29]. For other experimental mammalian 
models and for human gene therapy, transgenic strategies remain limited or impractical.  
Viral gene delivery represents an effective, time-efficient and broadly applicable 
strategy to transduce post-mitotic neurons [77]. Additionally, when used in transgenic 
lines, viral gene delivery further expands the possible molecules expressed or different cell 
types targeted. A major challenge in developing viral gene delivery tools is the limited 
DNA packaging capacity of viral vectors [77, 134]. The use of cell-type specific promoters 
for viral gene delivery has been mainly limited to a few neuron types, because the large 
size and the complexity of natural promoters often leads to complications with viral 
packaging or transgene expression [18, 80]. We recently explored the use of microRNA 
(miRNA) regulation, a gene regulation mechanism orthogonal to promoter elements, to 
restrict gene expression to specific subsets of neurons, and illustrated the synthetic biology 
design principles involved [135]. This strategy is uniquely suited for virally delivered 
genetic classifiers, because miRNA recognition sites are small (~22 nt), and thus can be 
easily packaged in viral vectors. Additionally, miRNA targeting is highly engineerable: 
several miRNAs each with multiple recognition site repeats can be combined to regulate 
the expression of a single gene. Finally, miRNAs are particularly enriched in the 
mammalian brain compared to other organs [136], making them highly suitable for 
neuroscience applications.  
Here, we aim to develop a miRNA-guided neuron tag (“mAGNET”), to restrict 
transgene expression to cortical inhibitory (GABA+) neurons in the mouse neocortex. 




essential role in regulating neural activity, and their dysfunction has been implicated in 
various neurological and psychiatric disorders [14]. For example, abnormal loss of 
inhibition can lead to epilepsy [137]), and  imbalanced excitation and inhibition has been 
linked to autism spectrum disorders (ASD) [138, 139].  Transgenic mice models with 
selective expression of Cre-recombinase in specific interneuron subtypes have 
revolutionized our ability of targeting specific interneuron types using Cre-Lox genetic 
techniques [74]. However, it remains difficult to cross-breed these Cre transgenic driver 
lines with transgenic disease models to achieve a suitable genetic background for targeting 
specific cell types in disease models. Viral vectors, lentivirus or adeno- associated virus, 
have achieved some success in targeting interneurons using shortened or non-mammalian 
promoters [80, 127] and short cell-type specific enhancer elements [81-83]. Since miRNA 
regulation is orthogonal to promoter and enhancer regulatory elements, mAGNET 
represents a novel strategy to confine targeting specificity in viral vector designs.  
In this study, we developed a GABA-mAGNET that achieves 98% cortical 
interneuron targeting specificity in mice. To demonstrate the utility of this novel 
interneuron targeting tool, we targeted cortical interneurons in a Ube3a 2X Tg transgenic 
murine model of autism, where it is difficult to deploy transgenic Cre-Lox based cell type 
targeting strategy. We also found that these GABA-mAGNET designs using mice 
microRNA profiles were able to achieve >80% specificity towards cortical interneurons in 
rat cortex and hippocampus. Finally, to illustrate the possible application of our mAGNET 
targeting tool, we used it to perform a dual-color optogenetic manipulation of distinct 








3.3.1 hSyn-Driven Lentiviral GABA-mAGNET Achieves 91% Specificity in Targeting 
Cortical Interneurons in Mice 
Because miRNA regulation is an inhibitory mode of gene expression control, 
mAGNET targeting is accomplished by knocking down viral transgene expression in off-
target cells, rather than positively driving expression in target cells. Figure 8A illustrates 
the mAGNET gene targeting strategy, where we can utilize a constitutive promoter to drive 
gene expression non-specifically, and encode cellular specificity by including “signature” 
miRNA recognition sites within the 3’ untranslated region of the gene. Signature miRNAs 
are chosen based on their higher expression levels in off-target cells compared to the on-
target cells, and high ratios of expression between off and on target cells (see Sayeg et al). 
The designed mAGNET vector, when packaged as virus and injected at a specific location 
in the brain, leads to the production of transcripts in all infected cells. However, signature 
miRNAs in off-target cells inhibit gene expression by hybridizing to their complementary 
recognition sites within the mAGNET transcript. Conversely, the low level of signature 
miRNAs in the on-target cell type permits the mAGNET transcripts to be translated and 
expressed.  
To target GABA+ interneurons in the mouse cortex, we selected signature miRNAs 
by analyzing the neuron-type and brain region-specific miRNA expression profiles 




levels in excitatory neurons (greater than 1000 raw sequencing reads), and the highest 
ratios of expression in excitatory versus inhibitory neurons:  mir-128 and mir-221. Mir-
128 is one of the most highly expressed miRNAs in the mammalian brain [140], and is 
known to be an essential regulator of genes involved in neuronal excitability [118]. Mir-
221 is known to play a role in tumor angiogenesis [141], although its function in brain 
tissue is unknown. Our previous analysis showed that eight recognition sites each for the 
signature mir-128 and mir-221 are most effective in restricting gene expression to 
interneurons, and additional copies of recognition sites or inclusion of other miRNAs did 
not improve targeting specificity beyond ~80% [135]. Thus we utilized these miRNA 
cassettes for the mAGNET design here.  
To generate interneuron specific mAGNETs, we explored orthogonal elements of 
the gene delivery system, for example the constitutive promoter that drives mAGNET 
expression. Our previous designs utilized a strong EF1α promoter [135], chosen due to its 
robust, long-term expression from lentiviral vectors, and the fact that it is constitutively 
highly expressed in most tissues and cell types [142]. However, we reasoned that this 
strong promoter that drives transcription at a high rate may hinder effective regulation by 
endogenous neural microRNAs in off-target cells. We therefore employed the pan-
neuronal human synapsin 1 promoter (hSyn, 480 bp) (Figure 8B), which has been shown 
to mediate neuron-specific, long-term transgene expression from viral vectors [79].  
We packaged the hSyn-driven LV-GABA-mAGNET and LV-Control vectors as 
lentiviruses pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) envelope 




mice per virus) (Figure 8C). Fluorescence image analysis at two weeks post-injection 
revealed that virally transduced EGFP+ cells in the mAGNET-infected mice were more 
sparsely distributed compared to the control (Figure 8D). Furthermore, individual EGFP+ 
neurons were clearly visible without immunostaining and exhibit no observable difference 
in fluorescence intensity between the LV-GABA-mAGNET and LV-Control, or compared 
to previous EF1α-driven lentiviruses [135]. These results suggest that LV-GABA-
mAGNET virus infected cells within a comparable volume to the LV-Control virus, and 
the sparse distribution of EGFP+ cells is consistent with the distribution profiles of 
inhibitory neurons in the mammalian neocortex  
We assessed interneuron targeting specificity in brain slices, defined as the 
percentage of EGFP+ neurons that colocalize with an immunofluorescence marker for 
gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in mammalian 
cortex. We also independently quantified EGFP colocalization with a CamKIIα 
immunofluorescence marker for cortical excitatory neurons (off-target cells), as a 
secondary measure of verifying the identity of transduced neurons. The LV-Control vector 
(with no miRNA sites) exhibited ~12% EGFP colocalization with GABA 
immunofluorescence (and ~86% EGFP colocalization with CamKIIα 
immunofluorescence) (Figure 8E,F, Table 3), consistent with previous observations of a 
slight tropism towards excitatory neurons  [86, 135]. In contrast, the LV-GABA-mAGNET 
predominantly targeted interneurons in the mouse cortex with a 91 ± 3% target specificity 






Figure 8. mAGNET gene targeting strategy & LV-GABA-mAGNET targeting in the mouse 
cortex  
(A) Schematic of viral, microRNA-guided neuron tag (mAGNET) gene targeting strategy. (B) LV-GABA-
mAGNET (pHR-hSyn-EGFP-8X2C) and LV-Control (pHR-hSyn-EGFP) lentiviral vector designs; LTR = 
long terminal repeat, hSyn = human synapsin promoter, EGFP = enhanced green fluorescent protein, WPRE 
= woodchuck hepatitis virus post-regulatory element. miR128/miR221 refer to cassettes of eight respective 
miRNA recognition sites – note these sites are not shown to scale, they are enlarged for visualization 
purposes. (C) Schematics of stereotaxic virus injection sites in mouse cortex. (D) Confocal microscopy 
images showing comparison of LV-Control and LV-GABA-mAGNET lentivirus transduction in wild type 
mouse cortex (cortex 1 injection site). Scale bars are 250 µm. (E) Colocalization of EGFP+ cells with 
inhibitory (GABA) and excitatory (CamKIIα) cell markers in the wild type mouse cortex (n = 3 mice each). 
Scatter plot shows individual animals (circles) and mean (horizontal bar) ± SD. ***: p<0.0005 Pearson’s chi 
squared test. (F) Representative confocal images of EGFP fluorescence from cortical cells transduced with 
LV-Control, immunofluorescence of inhibitory (GABA) and excitatory (CamKIIα) cell markers, and 




3.3.2 AAV Packaging of GABA-mAGNET Achieves 98% Specificity in Targeting Cortical 
Interneurons in Mice 
We explored whether adeno-associated virus (AAV) packaging would further 
improve GABAergic interneuron targeting specificity, given that lentivirus exhibits some 
infection bias toward excitatory neurons in the mouse brain [86, 135]. AAV represents 
another recombinant viral vector commonly used in biomedical research and in human 
gene therapy clinical trials, with many capsid types that have been extensively 
characterized in the mouse central nervous system [86-89]. For example, AAV serotype 1 
(recombinant AAV using AAV-2 genome vector (Xue, Jason et al, 2001), pseudotyped 
with AAV-1 capsid protein) exhibits a nine-fold transduction bias towards inhibitory 
neurons when used at low titers [86]. More recently, a systematic comparison of AAV 
serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain demonstrated that AAV serotype 9 is the 
most efficient serotype for transducing cortical neurons, with slight tropism towards 
cortical inhibitory neurons [88]. We thus packaged the hSyn-driven GABA-mAGNET as 
AAV2.9 (using AAV-2 genomic backbone pseudotyped with AAV-9 capsid protein) to 
further improve interneuron targeting (Figure 9A). Because AAVs have a small packaging 
capacity (~5 kb) compared to lentivirus (~10 kb), the compact size of the miRNA 
recognition sites as well as the short hSyn promoter were especially important for enabling 
efficient packaging in AAVs.  
We injected the resulting AAVs at one cortical location (cortex 1 injection site, Fig. 
1c) in the mouse brain (n = 3 mice per virus), since we observed no differences in 




brain tissue at three weeks post-injection (Figure 9B). We found that the AAVs (Figure 
9B) infected a broader region around the injection site than lentivirus (Figure 8D), 
consistent with the ability to package AAVs at higher titers (AAV titer: ~2E12 vg/mL, ~0.5 
µL injected vs. LV titer: ~1E9 infectious particles/mL, ~1 µL injected). Of the AAV-
Control transduced EGFP+ cells, 23 ± 2% are GABA+ cells (76 ± 4% are CamKIIα) 
(Figure 9 C,D, Table 3), double the percentage of LV-Control transduced interneurons 
(~12%, Figure 8 E,F, Table 3), consistent with the general observation that AAV2.9 
exhibited a slight transduction bias toward cortical inhibitory neurons. Of the AAV-
GABA-mAGNET transduced EGFP+ cells, 98 ± 2% are GABA+ cells, (Figure 9 C,E, 
Table 3), in comparison to 91% achieved with the lentivirus construct (91 ± 3%, Figure 8 
E,G, Table 3). In order to determine whether AAV-GABA-mAGNET preferentially labels 
a particular interneuron subtype, we performed immunohistochemistry with non-
overlapping interneuron markers parvalbumin (PV) and calretinin (CR), and found that 
EGFP+ cells expressed these markers in the proportions corresponding to the expected 
distributions of these different interneuron subtypes in mouse cortex [10, 27, 143, 144] 
(Figure 13). The lack of specificity between different interneuron subtypes is expected 
based on the expression profiles of the chosen miRNAs in our mAGNET designs[92]. 
Together, these results demonstrate that the AAV-GABA-mAGNET is highly specific for 







Figure 9. Selective interneuron labelling with rAAV2.9 packaged GABA-mAGNET in the mouse 
cortex  
(A) AAV-GABA-mAGNET (rAAV2.9-hSyn-EGFP-8X2C) and AAV-Control (rAAV2.9-hSyn-EGFP) 
vector designs. (B) Confocal microscopy images showing comparison of Control and mAGNET AAV 
transduction in C57bL/6 wt mouse cortex (cortex 1 site). Scale bars are 250 µm. (C) Colocalization of EGFP+ 
cells with inhibitory and excitatory marker immune stains in the C57bL/6 wt mouse cortex (n = 3 mice each). 
Scatter plot shows individual animals (circles) and mean (horizontal bar) ± SD. ***: p<0.0005 Pearson’s chi 
squared test (see Methods). (D) Representative confocal images of EGFP fluorescence from cortical cells 
transduced with AAV-Control, immunofluorescence of inhibitory (GABA) and excitatory (CamKIIα) cell 




mAGNET. (F) AAV-CamKIIα-mRuby2 (rAAV2.9-CamKIIα-mRuby2) and AAV-GABA-mAGNET 
(rAAV2.9-hSyn-EGFP-8X2C) viral vectors co-injected in the cortex of Ube3a 2X Tg autism model mice 
and FVP wt littermates. (G) Confocal microscopy images showing cells transduced by AAV-CamKIIα-
mRuby2 (red) and AAV-GABA-mAGNET (green) in the cortex (cortex 1 site) in a Ube3a 2X Tg autism 
model mouse vs. FVP wt littermate. Scale bars are 250 µm. (H) Colocalization of EGFP from AAV-GABA-
mAGNET with the GABA immunofluorescence, or mRuby2 from AAV-CamKIIα-mRuby2 in Ube3a mice 
(n = 2), and wt littermates (n = 3). Scatter plot shows individual animals (circles) and mean (horizontal bar) 
± SD. ns = no significance, Pearson’s chi squared test. (I) Representative confocal images of EGFP 
fluorescence from cortical cells transduced with AAV-GABA-mAGNET, mRuby2 fluorescence from 
cortical cells transduced with AAV CamKIIα mRuby2, immunofluorescence of an inhibitory (GABA) cell 
marker, and colocalization from a Ube3a 2X Tg mouse and wt littermate. Scale bars are 35 µm.  
 
3.3.3 AAV GABA-mAGNET Achieves 95% Specificity in Targeting Cortical Interneurons 
in a Transgenic Autism Mouse Model 
Viral vector-mediated gene targeting is especially useful (compared to the use of 
transgenic Cre-driver lines) for research in disease models, because it eliminates the 
complication of breeding crosses of suitable genetic backgrounds fulfilling both disease 
and driver genotypes. Accordingly, to demonstrate the utility of our AAV-GABA-
mAGNET in transgenic murine disease models, we assessed interneuron targeting in an 
autism model with an overexpression of the Ube3a ubiquitin ligase gene (Ube3a 2X Tg 
mice) [145], an autism risk gene that can lead to aberrant overexpression of its gene product 
E6AP protein.  Ube3a 2X Tg autism model exhibits core autism behaviors and recapitulate 
the cortical excitation/inhibition (E/I) imbalance known to be a hallmark of autism 
spectrum disorders [145, 146]. The molecular mechanisms leading to autistic phenotypes 
in Ube3a 2X Tg  animals are starting to be uncovered, and it was recently shown that 
reduced dendritic branching and spine density of cortical neurons may be involved [147].  
A viral vector capable of genetically labelling cortical interneurons in these mice would 




 To examine the targeting specificity of our GABA-mAGNET for cortical 
interneurons in this mouse model of autism, and to demonstrate the possibility of viral-
mediated labelling of multiple neuron subtypes, we co-injected AAV-GABA-mAGNET 
with AAV-CamKIIα-mRuby2  (Figure 9F), a virus that uses a shortened CamKIIα 
promoter [18] to drive expression of the red fluorescent mRuby2 reporter in cortical 
excitatory neurons. These AAVs were pre-mixed and co-injected at the cortex 1 location 
(Figure 8C) in adult Ube3a 2X Tg mice and wild type FVP littermate controls. We 
processed the brain tissue at three weeks post-injection, and quantified EGFP 
colocalization with GABA immunofluorescence. The total number of transduced EGFP+ 
neurons was similar between the Ube3a mice and wild type littermates (Figure 9G). Of the 
transduced EGFP+ cells, 96 ± 2% are GABA+ in the Ube3a 2X Tg mice, and similarly 95 
± 3% in the wild type littermates (Figure 9 H,I, Table 3). Together, these results suggest 
that signature miRNA expression is similar between the wild type and autistic transgenic 
mice, and between the FVP and C57b/L6 genetic background. Furthermore, we 
successfully labelled two neuron subtypes (inhibitory and excitatory neurons), illustrating 
how viral labelling tools like our GABA-mAGNET will allow further characterization of 
disease mechanisms and therapeutic strategies in this Ube3a autism model, and other 
transgenic disease models.  Overall, this demonstration highlights the applicability of our 
novel interneuron targeting viral vector in murine models of human disease, where whole-





3.3.4 Interneuron Targeting with GABA mAGNET in the Rat Brain 
Rats are a preferred animal model for some behavioral neuroscience research, due 
to their greater cognitive abilities compared to mice, and thus there is a critical need for 
neuron-type targeting tools in this species. Neuron-type specific miRNA profiles are not 
yet available for rats, so we could not design a GABA-mAGNET specifically for this 
species. However, signature miR-128 chosen from the mouse data is known to be highly 
expressed in the rat cortex [148]. There is known to be a high degree of miRNA sequence 
conservation across mammals and especially between rodents [91, 148], and thus we 
hypothesized that cell-type specific miRNA expression profiles might also be similar, and 
that our mouse-derived GABA-mAGNETs might achieve some degree of interneuron 
specificity in the rat brain. We injected LV-Control and LV-GABA mAGNET in wild type, 
adult rats (n = 3 per virus) at two cortical sites equivalent to the coordinates in the mice 
(see Supplemental Methods). We observed that labelled neurons were much sparser in the 
mAGNET animals compared to the Controls over a comparable tissue volume (Figure 
10A). Quantification of immunostaining in brain slices revealed that the LV infection bias 
toward excitatory neurons was less pronounced in the rats: LV-Control virus transduced 
82 ± 2% CamKIIα+ cells and 16 ± 3% GABA+ cells (Figure 10 B,C, Table 3). Of the 
EGFP+ cells transduced by LV–GABA-mAGNET, 74 ± 3% are GABA+ (Figure 10 B,D, 
Table 3) across both cortical sites tested (Figure 12B). These results demonstrate that LV-
GABA-mAGNET exhibits preference towards interneurons in rats, despite being designed 
based on miRNA profiles from mice. The disparity in cortical interneuron targeting with 




knockdown efficiency differs between these two species.  
Next, we tested AAV-GABA-mAGNET in the wild type rat cortex. While AAV9 
has been shown to preferentially infect inhibitory neurons in the mouse cortex, the neuron-
type tropism of this AAV serotype in the rat cortex is unknown. We therefore further tested 
our rAAVs at both cortical locations. AAV-mAGNET targeted a sparser population of cells 
than the AAV-Control (Figure 10E) and transduced a broader region than the 
corresponding lentivirus (Figure 10A). Immunohistology quantification of the AAV-
Control revealed that rAAV2.9 has a slight interneuron tropism in rats (Figure 10 F,G, 
Table 3) compared to the LV-Control, and an improved interneuron targeting of 82 ± 2% 
(Figure 10 F,H, Table 3) (compared to 74 ± 3% with LV-GABA-mAGNET, Figure 10 
B,C). Again, we did not observe any differences in interneuron targeting across the two 
cortical injection sites (Figure 12C).  
 It was unclear whether our GABA-mAGNET would be effective for targeting 
interneurons in other brain regions, where cell-type specific miRNA profiles are unknown. 
In fact, we found that none of our previous designs showed significant interneuron 
targeting in the mouse hippocampus [135]. This was not surprising given that expression 
levels of miR-128 and miR-221 are significantly lower in the mouse hippocampus 
compared to cortex [91]. Interestingly, it was shown that VSVG pseudotyped lentiviruses 
transduce primarily cells in the subgranular zone of the hippocampus [84], which may have 
contributed to the lack of observed interneuron targeting with our lentiviral vectors. In rats, 
hippocampal miR-128 expression is ~40% of cortical expression [148], so we hypothesized 




injected rAAVs in the hippocampus region (Figure 14A) (same animals as that received 
injection in the cortex in Figure 10E-H), and saw a significant difference in the number of 
neurons transduced with the AAV-mAGNET compared to the AAV-Control (Figure 14B). 
In fact, the AAV-Control transduced a smaller proportion of interneurons in the 
hippocampus (8 ± 2%, Figure 14 C,D, Table 3) compared to the cortex (21 ± 4%, Figure 
10F,G, Table 3). However, the AAV-GABA-mAGNET preferentially targeted GABA 
neurons in the hippocampus, exhibiting 80 ± 5% EGFP/GABA colocalization (Figure 14 
C,E, Table 3), similar to the results obtained in the rat cortex (82 ± 2%, Figure 10F,H, 
Table 3). Together, these results demonstrate that miRNA-based gene targeting exhibits 
some cross-species and cross-brain region functionality, and further cell-type and brain-
region specific miRNA profile data in rats would facilitate the design of mAGNETs with 






Figure 10. Interneuron targeting with GABA-mAGNETs in the rat cortex  
(A) Confocal microscopy images showing comparison of LV-Control and LV-mAGNET transduction 
in rat cortex (cortex 1 site). Scale bars are 250 µm. (B) Colocalization of EGFP+ cells with inhibitory 
and excitatory marker immune stains in rat cortex (n = 3 rats each). Scatter plot shows individual animals 
(circles) and mean (horizontal bar) ± SD. ***: p<0.0005 Pearson’s chi squared test (see Methods). (C) 
Representative confocal images of EGFP fluorescence from cortical cells transduced with LV-Control, 
immunofluorescence of inhibitory (GABA) and excitatory (CamKIIα) cell markers, and colocalization. 
Scale bars are 35 µm. (D) Same as (C), for cells transduced with LV-GABA-mAGNET. (E-H) Same as 





3.3.5 GABA-mAGNET Enable Dual-Color Optogenetics in Two Neuron Subtypes in Wild 
Type Mice 
To demonstrate the applicability of GABA-mAGNET, we performed dual-color 
optogenetic manipulation of two cell types in the wild type (non-transgenic) mouse cortex. 
We co-injected two AAVs in the motor cortex: AAV-Jaws-GABA-mAGNET, which 
mediates targeted expression of Jaws-mRuby2 in inhibitory neurons and allows them to be 
silenced with pulses of red light, and AAV-CamKIIα-ChR2, which mediates targeted 
expression of ChR2-EGFP in CamKIIα+ excitatory neurons and allows these cells to be 
activated with pulses of blue light (Figure 11A). We chose this pair of rhodopsins (Jaws 
and ChR2) because they exhibit minimal spectral overlap [70, 71]. Immunostaining results 
confirmed that of the mRuby2+ mAGNET transduced neurons, 95 ± 3% are GABA+.  
Four weeks after injection, we recorded local field potentials (LFPs) while silencing 
inhibitory neurons (expressing Jaws) with red laser illumination, or activating excitatory 
neurons (expressing ChR2) with blue laser light illumination, or both simultaneously. We 
predicted that either silencing the inhibitory neurons or activating the excitatory neurons 
could increase the excitability of the neural circuit and entrain LFP oscillations at the 
frequency of illumination. We thus applied two different illumination patterns: a 1-second 
long pulse train at 40 Hz, or a single 200 ms long pulse. In mAGNET mice, 40 Hz 
illumination with either the red or the blue laser alone was sufficient to induce oscillations 
centered at 40Hz, and concurrent illumination with both blue and red lasers induced 
stronger oscillations (Figure 11C). Interestingly, we also observed strong, slow oscillations 




blue laser illumination, but not with the red laser alone (Figure 11Cii, LFP trace). To 
examine the effects of laser illumination on LFP oscillations across animals, we calculated 
the normalized powers during the one-second windows before and after the laser 
illumination onset. When silencing the inhibitory neurons with 40 Hz red laser illumination 
in mAGNET mice, we observed an increase in LFP oscillation power, centered at 40 Hz 
(n = 6) (Figure 11Dii, left). Activating the excitatory neurons with 40 Hz blue laser 
illumination, either alone or simultaneously with silencing the inhibitory neurons, 
produced stronger oscillations (Figure 11Dii, middle and right, respectively). We further 
calculated the LFP power at gamma frequencies (30 to 50 Hz). In mAGNET mice, 
silencing inhibitory neurons at 40 Hz induced significant gamma oscillations (p<0.05, 
Wilcoxon rank sum test) (Figure 11E, left), and activating excitatory neurons produced a 
larger enhancement (p<0.05, Wilcoxon rank sum test) (Figure 11E, middle). The combined 
effect of both is similar to that observed upon activating the excitatory neurons alone 
(Figure 11E, right). These results demonstrate that both Jaws and ChR2 were expressed at 
functional levels in the desired cell types and can be effectively optogenetically controlled, 
therefore miRNA regulatory cassettes did not hinder rhodopsin expression in the on-target 
cells. The same 40 Hz laser illuminations produced no change in sham mice (no virus 
injection), as expected (n = 5) (Figure 11Ci and Di).  
Across individual mAGNET mice, a 200 ms pulse illumination with red or blue 
laser alone only elicited small changes in the LFPs. However, simultaneous illumination 
with red and blue lasers consistently enhanced power at higher frequencies (Figure 11F). 




ms pulse of red laser illumination produced little effect (n = 6) (Figure 11Gii, left), whereas 
activating the excitatory neurons with a 200 ms pulse of blue laser induced a small increase 
in power (Figure 11Gii, middle). Simultaneous inhibitory silencing and excitatory 
activation induced strong oscillation over a wide frequency range (Figure 11Gii, right). At 
gamma frequencies, neither inhibitory silencing, nor excitatory activation alone was 
sufficient to produce significant change, but simultaneously silencing of inhibitory neurons 
and activation of excitatory neurons led to significantly stronger oscillations (p<0.05, 
Wilcoxon rank sum test) (Figure 11H). This summation phenomenon further confirms that 
both lasers were indeed affecting different populations of neurons. 200 ms laser 
illuminations in sham mice (without virus injection) produced no effects on LFPs or 
oscillations (Figure 11 Fi,Gi). Together, these results suggest that activation of excitatory 
neurons and inhibition of inhibitory neurons have an additive effect on network 
oscillations, when each perturbation produce small changes (Figure 11H). However, in a 
state where excitatory neurons were being driven strongly by ChR2 (40 Hz entrainment), 
silencing of inhibitory neurons failed to further enhance oscillation powers at gamma 











(A) AAV vector designs to selectively express Jaws-mRuby2 in cortical inhibitory neurons for silencing 
(Jaws- GABA-mAGNET, rAAV2.9-hSyn-Jaws-mRuby2-ER2-8X2C), and ChR2-EGFP in cortical 
excitatory neurons for activation (CamKIIα-ChR2, rAAV2.9-CamKIIα-ChR2-EGFP). These AAVs 
were co-injected into motor cortex at injection site 1 (Figure 8C) in C57bL/6 wt mice (n=6). (B) 
Representative confocal images of CHR2-EGFP expression, Jaws-mRuby2 expression, and 
immunostaining of GABA, the inhibitory cell marker. The merged image indicates their colocalization. 
Scale bars are 35 µm. (C) Examples of local field potential (LFP) recordings and spectrograms from a 
sham (non-injected, wt) mouse (ci) and from a mAGNET (virus-injected, wt) mouse (cii) during 40 Hz 
pulse train laser illumination. Both LFP trace and spectrogram were aligned to illumination onset. Open 
boxes above indicate the time window for calculating oscillation power and solid parts indicate 
illumination duration: pre-illumination (Pre), red laser illumination (R), blue laser illumination (B), and 
simultaneous red and blue laser illumination (R+B). (D) Normalized oscillation power during 40 Hz 
pulse train laser illumination across animals (sham: n = 5, mAGNET: n = 6). (E) Gamma oscillations 
(30-50 Hz) induced by 40 Hz pulse train laser illumination with red laser (left), blue laser (middle), or 
both (right) in sham and mAGNET mice (*: p<0.05, Wilcoxon rank sum test). Plot shows mean ± SEM. 
(F) Example LFP and spectrogram from a sham mouse (Fi) and a mAGNET mouse (Fii) during 200 ms 
pulse laser illumination (same mice as in c). (G) Normalized oscillation power during 200 ms pulse 
laser illumination across animals (sham: n = 5, mAGNET: n = 6). (H) Gamma oscillations (30-50 Hz) 
induced by 200 ms pulse laser illumination with red laser (left), blue laser (middle), or both (right) in 





In this study, we have developed GABA-mAGNET, a novel, miRNA-based, viral 
gene delivery tool that restricts transgene expression to cortical inhibitory neurons in mice. 
Building upon our previous exploration of the synthetic biology principles on designing 
signature miRNA binding site cassettes, we further explored promoter and viral packaging 
designs. Through such integrative optimization of mAGNET designs, we here report a 
miRNA-based gene targeting tool with >95% specificity towards cortical inhibitory 
neurons, defined as the percentage of AAV-GABA-mAGNET labelled cells are also 
GABA+, comparable to that achieved with whole animal transgenic techniques [74, 75]. 
This novel interneuron targeting tool is effective at labeling cortical interneurons with 96% 




targeting is difficult. We also demonstrate that GABA-mAGNET exhibits ≥80% 
interneuron specificity in the rat cortex and hippocampus. Given that GABA antibodies 
may not label all GABA+ cells, our estimated targeting specificity represents a 
conservative measure. Finally, to illustrate the possible application of the GABA 
mAGNET targeting tool, we used it to perform a dual-color optogenetic manipulation of 
distinct neuron subtypes in non-transgenic mice, highlighting the promise of miRNA-based 
gene targeting in basic brain research and translational applications.  
The novel, neuron-type specific, microRNA-based gene targeting strategy 
exemplified by our GABA mAGNET offers several unique advantages for gene delivery 
in the brain. First, miRNAs are particularly enriched in the mammalian brain [136]. 
Second, the small footprint of miRNA sites facilitates packaging into virus, an important 
mode of gene delivery to post-mitotic neurons. Finally, the combinatorial nature of miRNA 
regulation allows for the potential to engineer specificity. For example, our GABA-
mAGNETs could be designed to further specify targeting to subtypes of inhibitory neurons, 
such as parvalbumin, calretinin or somatostatin neurons by incorporating specific miRNA 
cassettes.  mAGNETs are orthogonal to other gene regulatory strategies using promoters 
and enhancer elements, and thus can be easily combined with other cell targeting strategies, 
and can be used in conjunction with cell-type specific Cre-driver transgenic lines [74, 149]. 
MiRNA-based genetic classifiers could also be useful for defining new cell types, based 
on complex biological miRNA profiles rather than the expression of single marker genes 
often unrelated to cell function. The recent development of single-cell RNA-seq in neurons 




methods for cell-type specific sequencing of miRNAs [150] holds the potential to help 
further characterize miRNA profiles in the brain, allowing the design of new mAGNET 
classifiers. 
We here systematically explored various elements of the mAGNET design, and 
found that carefully selected signature miRNAs (miR-128, miR-221), a moderate hSyn 
promoter and rAAV2.9 packaging together maximized interneuron targeting. The 
mAGNET strategies are orthogonal to several other viral targeting strategies, deploying 
short promoters and enhancer elements. For example, short Dlx enhancer elements taken 
from the distalless homeobox genes have been shown to be effective in targeting 
interneurons across several brain regions and species [81-83]. Because miRNAs and 
enhancer elements work orthogonally to regulate gene expression, it should be possible to 
combine these two approaches, for example by incorporating the 400bp long mDlx 
enhancer in front of the short hSyn promoter in our AAV-GABA-mAGNET vector to 
further improve interneuron targeting specificity, especially in rat hippocampus.    
To demonstrate the utility of our AAV-GABA-mAGNET, we performed in vivo 
dual-color optogenetics in two different neuron subtypes in non-transgenic mice (Figure 
9). As new optogenetic technologies such as spectrally shifted rhodopsins [70, 71, 151] 
have allowed increasingly complex and precise experiments, a need has arisen for methods 
to simultaneously manipulate independent neuron subtypes in the same animal. Transgenic 
techniques have been used to deliver rhodopsins to specific subgroups of cells, mostly 
based on transgenic CRE/lox [152] or activity-dependent c-fos/TRAP systems [153, 154]. 




labelling techniques to optogenetically manipulate separate neuron subtypes in the wild 
type mouse brain. It also worth noting that mAGNETs alone could achieve multiple cell 
subgroup labeling, as long as each target subgroup has a distinct miRNA profile. We 
recorded LFPs while optogenetically silencing inhibitory neurons expressing Jaws 
(labelled with the GABA mAGNET), activating excitatory neurons expressing ChR2, or 
both. Interactions and synchronized activity between excitatory and inhibitory neurons are 
known to be crucial for generating neural oscillations [155]. The results of our experiment 
upon stimulating excitatory neurons at 40 Hz is consist with previous reports that periodic 
stimulation with blue laser light can activate and entrain ChR2-expressing neurons [58], 
and LFP oscillations [156]. Interestingly, we also found that periodic silencing of the 
inhibitory neurons could also entrain cortical rhythms, likely through disinhibition of the 
excitatory neurons and/or post-illumination rebound of inhibitory neurons [70], or both. 
The observation that silencing inhibitory neurons produced less impact than activating 
excitatory neurons could potentially be due to the fact that inhibitory neurons only 
constitute a small fraction of the neural population (<20%).  
We demonstrated that AAV-GABA-mAGNET targets cortical interneurons in a 
transgenic Ube3a mouse model of autism (Figure 9). Viral gene targeting tools are 
especially valuable in murine disease models, due to challenges in cross-breeding genetic 
disease model animals with other transgenic cell type targeting lines (such as Cre 
recombinase driver lines). Our AAV co-delivery experiment demonstrates that AAV-
GABA-mAGNET could be applied with other viral cell-type labelling tools in a mouse 




imbalance, a known feature of the disorder [146]. In fact, this novel gene targeting tool can 
be applied in a variety of murine transgenic disease models to study disease mechanisms 
[14].  
The mouse-derived GABA-mAGNETs developed here also exhibited interneuron 
preference in the rat cortex (~74-82%, Figure 3) and hippocampus (~80%, Figure 14). This 
suggests that miRNA-based targeting has potential in other animal models, including 
species where transgenic targeting is not possible or more difficult. Although genetic 
engineering techniques such as CRISPR are yielding some promising results in rats [157] 
and nonhuman primates [158], transgenic targeting has historically been difficult in these 
species. While the GABA-mAGNET was not as specific in the rat brain as in the mouse, it 
may still provide a useful interim research tool. In the future, systematic analysis of cell-
type and brain-region specific miRNA profiles in other species would greatly advance the 
design of mAGNETs for use in species where transgenic options are less readily available. 
Finally, advancements in viral gene targeting are especially important for human 
gene therapies, given that viruses are one of the primary DNA delivery vehicles used in 
humans. The ability to virally target therapeutic transgenes to specific neuronal populations 
in the human brain holds the potential for developing better treatment of neurodegenerative 
and neuropsychiatric disorders. Recent evidence indicates that AAV9 serotype, the one 
used here, may bypass the blood-brain barrier when injected intravenously [159], 
highlighting the translational potential of novel viral vector designs. MicroRNAs are 
currently being explored as a mechanism of achieving tissue-specific gene targeting for 




this strategy could be developed further to target subtypes of cells within the same tissue, 
such as the brain. In the future, mAGNETs could also be designed to target therapeutic 
transgenes such as virally encoded CRISPR-Cas9 systems [161, 162] to neuron subtypes. 
The GABA mAGNET presented here provides a novel means of virally labelling 
interneurons in the rodent brain, and opens the door for the development of many more 




Viral vector construction. Standard molecular cloning procedures (PCR and 
restriction enzyme digestion) were used to construct genetic classifiers in viral vectors 
unless otherwise stated. LV GABA mAGNET and LV Control vectors were made by 
replacing the 1.2 kb Ef-1α promoter in our previously published 8X2C mAGNET 
(Addgene plasmid #67955) with human Synapsin 1 promoter (Addgene plasmid #86537) 
via EcoRI and BamHI restriction sites. The expression cassettes (including promoter, 
transgene and miRNA sites for mAGNET) from the resulting LV GABA mAGNET and 
LV Control vectors were amplified via PCR and inserted between the ITRs of an AAV-2 
genomic vector obtained from Roger Tsien (Addgene plasmid #50954) via BglII and 
HindIII restriction sites. To produce the AAV CamKIIα mRuby2 vector, the CamKIIα 
promoter obtained from Ed Boyden (Addgene plasmid #64545) was cloned into the AAV-
2 vector simultaneously with an mRuby2 reporter obtained from Michael Davidson 
(Addgene plasmid #54771) via EcoRI, AscI and Sbf1 sites. To generate Jaws GABA 




(Addgene plasmid #65013) and fused to mRuby2, replacing EGFP in the AAV GABA 
mAGNET and AAV Control vectors via a Gibson reaction. Finally, the CamKIIα ChR2 
vector was produced by replacing the mRuby2 transgene in the AAV CamKIIα mRuby2 
vector with ChR2-EGFP obtained from Ed Boyden (Addgene plasmid #58881) via AscI 
and SpeI sites. All new viral vectors produced here will be deposited to PubMed and 
Addgene.  
Lentivirus preparation. Replication-incompetent lentivirus was packaged via 
triple transfections of the LV-hSyn-EGFP or LV-hSyn-EGFP-8X2C lentiviral transfer 
plasmid, plasmid pMD2.G encoding for VSV-G pseudotyping coat protein (Addgene 
plasmid #12259), and pDelta 8.74 (Addgene plasmid #5682) helper packaging plasmid, 
into HEK293FT cells (LifeTechnologies, R700-07) using TransIT-293 transfection reagent 
(Mirus Bio LLC, MIR 2700), and then purified through ultracentrifugation. Viral 
transduction was first tested in primary rat neuron cultures before in vivo injections were 
performed, and viral titer was estimated to be ~1E9 transducing units/mL based on 
transduction efficiency of serial dilutions [132].  
Adeno-associated virus (AAV) preparation. Replication-incompetent AAV was 
packaged via triple transfections of the AAV-2 transfer vector (rAAV2.9-hSyn-EGFP-
8XC, rAAV2.9-hSyn-EGFP, rAAV2.9-CamKIIα-mRuby2, rAAV2.9-hSyn-
Jaws_mRuby2-8X2C, or rAAV2.9-CamKIIα-ChR2_EGFP), cap-9 plasmid encoding the 
Rep and Cap proteins (serotype 9), and pXX680 helper packaging plasmid, into 
HEK293FT cells (LifeTechnologies, R700-07) using TransIT-293 transfection reagent 




lysed via three freeze-thaw cycles followed by sonication, and virus was purified from the 
lysate via PEG precipitation (System Biosciences, LV810A-1). Viral titer was determined 
via rt-PCR (Takara, AAVpro Titration Kit Ver.2) to be ~2E12 vg/mL. Viral transduction 
was first tested in primary rat neuron cultures before in vivo injections were performed.  
Stereotaxic virus injection surgeries. All procedures were done in accordance 
with the National Institutes of Health Guide for Laboratory Animals and were approved by 
the Boston University Institutional Animal Care and Use and Biosafety Committees. Mice 
used for were adult female C57bL/6 wild type mice (Taconic Biosciences) eight weeks old 
at time of injection unless otherwise stated. We injected lentivirus at two locations in the 
mouse neocortex: cortex1 (+1.000 mm ML, +1.800 mm AP, -1.250 mm DV) and cortex2 
(+1.000 mm ML, -1.500 mm AP, -0.900 mm DV). Approximately 1.0 µL (1E6 infectious 
particles) of lentivirus was injected per site. Three mice were injected per condition (n = 6 
mice total). We injected the AAV GABA mAGNET or AAV Control only at the cortex 1 
coordinates in the mouse cortex. Approximately 0.5 µL of virus was injected for each AAV 
(1E9 viral particles). Three mice were used per virus (n = 6 mice total).  
Mice used in Figure 9F-I were adult female FVP/NJ-Tg(Ube3a)1Mpan/J autism 
mice (The Jackson Laboratory stock #019730) or adult female FVP/NJ wild type 
littermates (The Jackson Laboratory stock #001800), twelve weeks old at time of injection. 
To obtain Ube3a 2X Tg animals, heterozygous (1X Tg) males were mated with 
heterozygous (1X Tg) females, and the offspring homozygous (2X Tg) animals were used 
for experiments. We injected ~1.0 µL of AAV GABA mAGNET premixed with AAV 




2X Tg autism mice and three wild type littermates were used (n = 5 mice total).  
All rats used were adult male Sprague-Dawley wild type rats, eight weeks old at 
the time of injection. We injected lentivirus at two locations in the rat brain: cortex 1 
(+1.700 mm ML, +2.800 mm AP, -1.600 mm DV) and cortex 2 (+1.500 mm ML, -2.500 
mm AP, -1.600 mm DV), analogous to the corresponding cortical injection sites in the 
mice. ~1.0 µL of lentivirus was injected per site. Three rats were injected per lentivirus (n 
= 6 rats total). ~0.5 µL AAV GABA mAGNET or AAV Control was injected at both 
cortical sites in the rats and additionally at a site in the hippocampus (+1.500 mm ML, -
2.500 mm AP, -3.300 mm DV). Three rats each were used for each AAV virus (n = 6 rats 
total). All injection surgeries were performed using sterile surgical techniques under 
isoflurane anesthesia, and were accomplished using a standard rodent stereotaxic 
instrument and an automated microinjection syringe pump (World Precision Instruments, 
UMP3-1).  
Immunohistology. At two weeks (LV) or three weeks (AAV) post-injection, 
animals were sacrificed and perfused with 4% PFA. Brains were post-fixed in 4% PFA for 
three hours, cryoprotected in a 30% sucrose, then flash froze in OCT. Frozen brains were 
sectioned (coronal) at 50 μm on a cryostat and slices were stored in PBS+0.05% sodium 
azide. Brian slices were stained with antibodies against GABA (Sigma, A2052, 1:1000) or 
CamKIIα (Santa Cruz Biotech, sc-13082, 1:50), followed by Alexa Fluor 568 goat anti-
rabbit secondary antibody (Invitrogen A21071, 1:1000) and ToPRO-3 nuclear dye (Life 
Technologies, 1:5000), or just Alexa Fluor 633 goat anti-rabbit secondary antibody 




as Alexa Fluor secondary antibodies) were used for mice and rat brain slices, as they were 
shown by the manufacturer to be reactive in both species. For parvalbumin (PV) and 
calretinin (CR) staining, brain slices were co-stained with a mix of PV (SWANT GP72 
1:2000) and CR antibodies (SWANT 7697 1:1000), and then a mix of secondary 
antibodies: Alexa Fluor 568 goat anti-guinea pig (Invitrogen A11075 1:1000) and Alexa 
Fluor 633 goat anti-rabbit secondary antibody (Invitrogen A11011, 1:1000).  
Confocal imaging and quantification. Confocal imaging was performed on an 
Olympus FV1000 scanning confocal microscope, using a 10X lens or 60X water 
immersion lens. Z-stacks were taken by imaging at 2 μm intervals throughout the slices. 
Confocal image stacks were taken at least 150 µm away from the center of the injection 
site for LV, and at least 250 µm away from the center of the injection site for AAV. 
Consistent laser settings were used for all imaging sessions: 488 nm laser 3.5%, 350 V; 
543 nm laser 13%, 600 V; 633 nm laser 5%, 600V. EGFP+ cell bodies were identified by 
comparison with ToPRO-3 nuclear staining, then each identified EGFP+ cell was 
categorized as immunopositive or immunonegative for the antibody stain. Note that 
staining for each immune marker (ex. GABA, CamKIIα) was performed on separate 
cortical brain slices unless otherwise stated. Immunopositive cell counts were pooled 
across slices stained for the same marker for each animal, and normalized to the total 
EGFP+ cell count across those slices. In this way, the proportion (%) of EGFP+ (or 
labelled) cells that colocalize with each immunomarker was calculated independently. 
Conversely, we determined that the cortical interneuron transduction efficiency of our 




GABA+ cells expressing the reporter, consistent with the general observation of the overall 
transduction efficiency of AAVs. For each animal, we analyzed at least 1-4 non-
overlapping confocal stacks from each of 2-6 slices per injection site. A similar number of 
cells (at least 50 EGFP+ cells per animal, see Statistical analysis) at similar distances from 
the injection site (~150 – 250 µm for LV and ~250 – 350 µm for AAV) were analyzed for 
each animal. All hippocampal images were taken in the CA1 area.  
Statistical analysis. To determine the minimal sample size (number of animals) 
needed to ensure adequate power to detect an inhibitory neuron targeting effect, we 
performed a power analysis with the following parameters: mean control group estimated 
value = 0.2, mean experimental group estimated value = 0.8, expected standard deviation 
= 0.05, alpha = 0.05, power = 0.8, 2 sided test. Randomization and investigator blinding 
were not considerations of this study design.  
A chi squared test of independence with one degree of freedom (as cortical neurons 
examined are either excitatory or inhibitory) requires an expected frequency of at least 10 
to produce reliable approximations, and because inhibitory cells make up approximately 
20% of neurons in the cortex and hippocampus, 50 neurons per mouse in each test condition 
was determined to be the minimum sample size. The Pearson’s chi squared test statistic 
with one degree of freedom was calculated for interneuron targeting in each condition 
(Table 3) by taking the difference between the observed number of counts for inhibitory 
cells compared to the expected distribution of 20% inhibitory cells, to determine the 




Optogenetics and electrophysiology. All mice used were adult female C57bL/6 
wild type mice. At eight weeks old, mAGNET mice (n = 6) were injected with ~1.0 µL an 
equal mixture (1E9 viral particles each) of AAV Jaws GABA mAGNET and AAV 
CamKIIα ChR2 at cortex 1 coordinates (+1.000 mm ML, +1.800 mm AP, -1.250 mm DV). 
During the same surgery, a metal pin was implanted in the opposite hemisphere serving as 
recording ground, and a head plate was secured to the animal’s skull via dental cement. 
Control animals (n = 5) underwent surgery for metal ground pin and head plate 
implantation, but did not receive any viral injection.  
After 6-7 weeks post-surgery, recordings were performed with a borosilicate glass 
electrode (G100F-4, Warner Instruments; 1-5 MOhm and filled with saline) to avoid laser 
light induced artifact on metal electrodes, while mice were awake and head-fixed. Signals 
were amplified with a Multiclamp 700B (Molecular Device), digitized with a Digidata 
1440A, and recorded with the pClamp software (Molecular Device) at 20 kHz. Optogenetic 
light illumination for ChR2 and Jaws were achieved with a 473 nm blue laser (Shanghai 
Laser) and a 635 nm red laser (Shanghai Laser), respectively. To deliver light, two optical 
fibers (200 µm in diameter, ThorLabs) were coupled with the glass electrode. The tips of 
the optical fibers were positioned about 500 µm above the tip of the glass electrode, and 
the power at the optic fiber tips was adjusted to 10 mW for both blue and red light. The 
fiber-electrode bundle was insert into the viral injection site (+1.000 mm ML, +1.800 mm 
AP, -0.400 DV).  Illumination patterns consisted of three conditions: red laser alone to 
silence inhibitory neurons (R), blue laser alone to activate excitatory neurons (B), and both 




50% duty cycle, or a single constant pulse of 200 ms in duration). The illumination patterns 
were generated by a function generator (33210A Agilent), which was triggered by pClamp 
to maintain precise timing of the illumination patterns. Each trail contained three 
illumination periods (red laser alone, blue laser alone, and red + blue lasers) with 10 
seconds intervals between each illumination and 5 second window before the first 
illumination period and after the last illumination period. The illumination order was 
randomized across mice, and each mouse underwent 10 trials of each illumination pattern. 
Electrophysiology data analysis. LFP data analysis was performed in Matlab 
with Chronux (http://chronux.org/). Spectrograms were generated with mtspecgramc 
(tappers=[3 5], window size=500 ms, step size=5 ms) and normalized as decibel (dB) 
using: 




where powermax is the maximum value of the LFP power during each trial. The power 
pre- and post-stimulation for each trial was calculated with mtspectrumc (tappers=[3 5]) 
from LFP signals during the 1- second windows before and after illumination onset, 
respectively. To remove the variabilities between individuals, we further normalize the 
power for each illumination as follows: 




where powerbaseline is the averaged power during the 1-second window prior to the pre-
illumination window. The powers were first averaged across trials to obtain the 




3.6 Supporting Information 
3.6.1 Supporting Tables and Figures 
 
Figure 12. Consistency in interneuron targeting across cortical injection sites  
(A) – (C) Comparison of EGFP colocalization (%) with immunohistology markers for inhibitory 




chi squared test) between the two motor cortex sites injected for (A) lentiviruses in the mouse cortex, 
(B) lentiviruses in the rat cortex, or (C) AAVs in the rat cortex. Note that AAVs were only injected at 
one site in the mouse cortex, so there is no comparison data across cortical sites. Scatter plots show 




Figure 13.  AAV-GABA-mAGNET labelling of interneuron subtypes by cortical layer 
(A) Representative confocal images of EGFP fluorescence from cortical cells transduced with AAV 
GABA mAGNET, immunofluorescence of non-overlapping PV and CR cell markers, and 
colocalization at low (top) and high (bottom) magnification. Top scale bars are 210 µm. Bottom scale 
bars are 35 µm. (B) Colocalization of EGFP (%) with PV and CR marker immune stains in the wild 
type mouse cortex (n = 3 mice). Scatter plot shows individual animals (circles) and mean (horizontal 
bar) ± SD. Colocalization of EGFP (%) with immunohistology markers for sub-types of inhibitory 
neurons – parvalbumin (PV) and calretinin (CR) – follows the expected distribution of these cells in 







Figure 14. AAV-GABA-mAGNET targeting in the wt rat hippocampus 
(A) Schematic of stereotaxic virus injection sites in rat hippocampus. (B) Confocal microscopy images 
showing comparison of AAV-Control and AAV-mAGNET-transduction in rat hippocampus. Scale bars 
are 250 µm. (C) Colocalization of EGFP with inhibitory (GABA) and excitatory (CamKIIα) neuron 
marker immune stains in the rat hippocampus (n = 3 rats each). Scatter plot shows individual animals 
(circles) and mean (horizontal bar) ± SD. ***: p<0.0005 Pearson’s chi squared test (see Methods). (D) 
Representative confocal images of EGFP fluorescence from cortical cells transduced with AAV-
Control, immunofluorescence of inhibitory (GABA) and excitatory (CamKIIα) cell markers, and 






Table 3. Summary of GABA-mAGNET Interneuron Labelling 
Virus Type Animal and Injection site GABA Colocalizatione,f 
  mAGNET Control 
LV 
 
C57BL/6 wt mousea 
(cortex 1 & 2)d 
91 ± 3% *** 
(339) 
12 ± 3% 
(384) 
Sprague-Dawley wt rata 
(cortex 1 & 2) d 
74 ± 3% *** 
(337) 




C57BL/6 wt mousea 
(cortex 1) 
98 ± 2% *** 
(184) 




96 ± 2%  
(134) 
NA 
FVB/NJ wt mousec 
(cortex 1) 
95 ± 3%  
(177) 
NA 
Sprague-Dawley wt rata 
(cortex 1 & 2) d 
82 ± 3% *** 
(348) 
21 ± 4% 
(411) 
Sprague-Dawley wt rata 
(hippocampus) 
80 ± 5% *** 
(176) 
8 ± 2% 
(174) 
 
a n = 3 animals each for GABA mAGNET and Control virus 
b n = 2 animals, GABA mAGNET virus only 
c n = 3 animals, GABA mAGNET virus only 
d data are pooled across both cortical injection sites 
e numbers in parentheses indicate the number of EGFP+ neurons analyzed (at least 50 per animal per 
injection site, see Methods) 
f *** p<0.0005 Pearson’s chi squared test (see Methods). 
 
3.6.2 Validated Viral Vector Sequences 


















































































































































































































































































































































































CHAPTER 4 – A NOVEL CAMKIIα+ NEURON SUBTYPE WITH LOW 
EXPRESSION OF MICRORNA-128 IN THE MOTOR CORTEX 
 
4.1 Abstract 
New biological insights and genetic technologies allow increasingly specific 
characterization of neuron diversity in the brain. Here, we demonstrate the use of the 
microRNA-guided neuron tag (mAGNET) strategy to define a novel neuron subtype on 
the basis of microRNA (miRNA) expression profile. Specifically, we identify and 
characterize a novel subset of motor cortex neurons in the mouse brain that expresses the 
alpha subunit of calcium/calmodulin-dependent protein kinase type II (CamKIIα) and has 
low expression of miR-128, which is known to be related to neuronal excitability. Using a 
mAGNET, we label these neurons (low-miR-128-CamKIIα+, Lm128C) in the mouse 
motor cortex, and compare their physiological properties to the overall CamKIIα 
population via in vivo calcium imaging in behaving mice, slice recordings, and 
immunofluorescence staining. We illustrate that sparsely distributed Lm128C cells in 
motor cortex exhibit elevated in vivo activity and ex vivo spike rates, as well as stronger 
correlation between their activities. Therefore, Lm128C cells constitute a novel subset of 
cortical CamKIIα+ neurons. Interestingly, the biophysical properties of Lm128C neurons 
closely resemble those of fast-spiking interneurons (FSIs), and immunofluorescence 
staining confirms that half of Lm128C cells are GABAergic and express the FSI marker 
parvalbumin (PV) in addition to CamKIIα. Thus, these cells provide evidence that 
CamKIIα is expressed outside of principal excitatory cells in the mammalian cortex, 




demonstrate a novel classification technique to characterize neurons with distinct miRNA 
profiles.  
4.2 Introduction 
The brain is composed of many specialized neuron subtypes, which together give 
rise to complex circuit dynamics and functions. Classification and characterization of 
neuronal cell types is therefore important for understanding the mechanisms of brain 
function. Neurons have traditionally been classified according to many criteria, including 
location, morphology, neurotransmitter contents and electrophysiological properties [8]. 
With the advance in genetic tools, neuron types have been increasingly defined based on 
the expression of molecular markers, which when associated with functional phenotypes 
allows detailed characterization of functionality with genetic tools. However, neurons that 
express a common marker gene can still exhibit great diversity [10, 24], and many marker 
genes are only loosely related to the function of the neuron subtype that they label. For 
example, parvalbumin (PV) is a calcium (Ca) binding protein that is used as a cell-type 
specific marker gene for fast-spiking interneurons (FSIs) [163], however the function of 
parvalbumin protein has not been specifically linked to the inhibitory or the fast spiking 
nature of these neurons.  
Transcriptomic profiling has started to reveal that the genetic diversity of neurons 
is too great to be encompassed by single marker genes. Early efforts focused on profiling 
gene expression from small cell populations taken from precise dissections [164, 165], or 
pools of sorted cells expressing common markers [166-168]. However, population level 




recently, advancements in single-cell transcriptomic profiling have enabled the 
characterization of individual brain cells, revealing dozens of molecularly distinct classes 
of neurons [25, 26, 169-171]. For example, Zeisel et al identified 23 distinct neuron 
subclasses in mouse somatosensory cortex [26], and Tasic et al. identified 42 
transcriptionally distinct neuron types within mouse primary visual cortex. These newly 
identified neuron classes include many subtypes within the populations expressing major 
markers [25]. Single cell analysis studies underscore the genetic and functional diversity 
among cortical neurons, and highlight the importance of developing neuron subtype 
classification and characterization methods that can link gene expression profiles and 
functional properties.  
Here, we demonstrate the use of the miRNA-guided neuron tag (mAGNET) 
strategy as a means of identifying subtypes of neurons in vivo on the basis of miRNA 
expression, highlighting the potential of classifying cells by linking physiologically 
relevant marker genes and network regulatory elements. miRNAs are small, non-coding 
RNAs that inhibit gene expression by binding to complementary recognition sites within 
mRNA transcripts, leading to transcript degradation or stalled translation. miRNAs have 
emerged as an important gene regulation mechanism, and it is now known that a single 
miRNA can regulate several genes within a pathway, or even multiple related pathways 
[112]. Because miRNAs are highly abundant in the mammalian brain and tend to regulate 
networks of related genes, they can provide a useful molecular signature to further 
delineate neuron subtypes. For example, miRNA expression has been used to discriminate 




been known to vary significantly across different brain regions [91, 148] and between 
different cell types [92]. Recently, miRNAs have also been used for Huntington’s disease 
diagnosis [172] and therapy [173].  Here, we explored the possibility of neuron subtype 
classification based upon microRNA (miRNA) expression, by identifying and 
characterizing a novel subset of CamKIIα+ neurons in mouse motor cortex which have low 
expression of miR-128.  
CamKII is a serine/threonine kinase essential for synaptic plasticity and memory, 
and a major component of the postsynaptic density in many neurons [21]. The alpha subunit 
(CamKIIα) is generally regarded as a marker gene for pyramidal excitatory neurons in the 
mammalian cortex [19, 20, 174], although little is known about the genetic diversity among 
cortical CamKIIα+ neurons. miR-128 is one of the most abundant miRNAs in the 
mammalian brain [140] and was recently found to be the second most highly expressed 
miRNA in mammalian neocortical CamKIIα+ neurons [92]. This miRNA has been shown 
to regulate the expression of several ion channels and signaling components of the 
extracellular signal-regulated kinase ERK2 network that govern neuronal excitability, and 
deficiency in this miRNA was shown to impact motor function [118]. We recently 
observed a small fraction of CamKIIα+ cortical neurons with naturally low expression of 
miR-128 [135, 175]. Here, we virally labelled these unique low-miRNA-128 CamKIIα 
(Lm128C) cells in the mouse motor cortex using a mAGNET, and compared their 
properties to the broader CamKIIα population, using in vivo calcium imaging, slice 
electrophysiological recordings, and immunofluorescence staining.  We found that 




co-express both PV and CamKIIα, and exhibit FSI activity patterns with elevated calcium 
event rate and greater intra-population activity correlation. 
 
4.3 Results 
4.3.1 Lm128C cells constitute a sparse population of CamKIIα+ neurons in mouse motor 
cortex 
 miR-128 has been shown to express at a high level in cortical CamKIIα+ neurons 
[92], and when incorporated in our miRNA-guided neuron tags (mAGNETs) could 
facilitate the exclusion of reporter gene expression in cortical excitatory neurons in mice 
[135, 175]. However, we consistently observed a small fraction of CamKIIα+ neurons that 
are labelled with mAGNETs containing miR-128 recognition site cassettes, indicative of 
lack of miR-128 expression in these labelled neurons [135]. To target and characterize this 
unique neuron subset that are CamKIIα+ and low in miR128 expression (LM128C 
neurons), we designed an AAV-Lm128C-mAGNET construct. Lm128C-mAGNET 
employs a 1.3 kb mouse CamKIIα promoter [18] and contains four repeats of the mIR-128 
recognition site (perfectly complimentary to the mouse miR-128 consensus sequence) 
within the 3’ untranslated region of the transgene (Figure 15 A,B). Using this Lm128C-
mAGNET design, all infected CamKIIα+ neurons produce mRNA transcripts, due to the 
chosen promoter. However, in cells with naturally high expression of miR-128, gene 
transcripts are knocked down; whereas in cells with low levels of miR-128, gene transcripts 




In order to statically label Lm128C neurons, we delivered a red fluorescent reporter 
(mRuby2), in the Lm128C mAGNET (Figure 15 A,B). Additionally, to facilitate in vivo 
calcium activity recordings from either Lm128C neurons or the total CamKIIα population, 
we also co-delivered another AAV bearing the calcium indicator GCaMP6f under the 
regulation of the CamKIIα promoter, either with or without the cassette of miR-128 sites 
(Figure 15 A,B). CamKIIα mice received a co-injection of Lm128C-mRuby-mAGNET 
with CamKIIα-GCaMP-Control vector (Figure 15A), and Lm128C mice received a co-
injection of Lm128C-mRuby2-mAGNET and Lm128C-GCaMP6f-mAGNET. All 
injections consisted of ~600 µL of 1:1 virus mixture (1E9 vg per virus) in superficial motor 
cortex (Figure 15C).  
After animals were sacrificed (at the conclusion of in vivo calcium imaging 
experiments, see Figure 16), we processed the brain tissue and imaged slices via confocal 
microscopy in order to visualize and quantify labelled Lm128C cells. We found that 
Lm128C neurons are sparsely distributed in mouse motor cortex, but localize to all cortical 
layers (Figure 15D vs. 15E). Furthermore, quantifying the proportion of Lm128C neurons 
(expressing both mRuby2 and GCaMP6f) within the total GCaMP6f expressing population 
in CamKIIα animals revealed that Lm128C neurons constitute 8 ± 2% of the CamKIIα 
neuron population in motor cortex (Figure 15F). This finding is supported by the fact that 
98 ± 2% of GCaMP6f expressing neurons also expressed mRuby2, suggesting that the co-







Figure 15. Lm128C vs. CamKIIα neurons in mouse motor cortex.   
A) AAV-CamKIIα-GCaMP-Control and AAV-Lm128C-mRuby-mAGNET vector designs. “CamKIIα” 
animals (n = 5) were co-injected with these two AAVs for in vivo calcium activity recordings of CamKIIα 
cells and static labelling of Lm128C cells. (B) AAV-Lm128C-GCaMP-mAGNET and AAV-Lm128C-
mRuby-mAGNET vector designs. “Lm128C” animals (n = 5) were co-injected with these two AAVs for 
both in vivo calcium activity recordings and static labelling of Lm128C cells. (C) Schematic of stereotaxic 
virus injection site in mouse motor cortex. (D) Representative low magnification (top) and high magnification 
(bottom) confocal microscopy images of the virus injection site in a CamKIIα mouse, showing GCaMP6f 
expression in CamKIIα neurons, mRuby2 expression in Lm128C neurons, and a merged overlay. (E) Same 
as (D), for a Lm128C mouse. (F) Quantification of mRuby2, GCaMP6f expressing cells to the total 
population of GCaMP6f expressing cells in CamKIIα and Lm128C animals. Data includes at least 50 neurons 
from each animal (n = 5 mice each CamKIIα and Lm128C), and are averaged across mice. Scatter plot shows 
individual animals (circles) and mean (horizontal bar) ± SD. 
 
4.3.2 Lm128C cells exhibit distinct calcium event dynamics, event rate and pairwise 
correlation during locomotion compared to CamKIIα neurons in mouse motor cortex 
To determine whether Lm128C neurons might represent a physiologically distinct 
subset of CamKIIα cells, we recorded and compared in vivo calcium activity from these 
two populations. Since Lm128C cells comprise a minor fraction (~8%) of the neurons 
labelled in CamKIIα animals, the effects observed in CamKIIα animals are primarily 




to differentiate the physiological differences between neurons with high versus low levels 
of miR-128 expression.  
The experimental timeline for in vivo calcium imaging recordings is summarized 
in Figure 16D. First, mice were co-injected with a combination of AAVs (see Figure 15 
A&B), including the genetically encoded calcium indicator GCaMP6f targeted either to 
the total population of CamKIIα neurons (“CamKIIα” animals) or specifically to CamKIIα 
neurons with low miR-128 (“Lm128C” animals) using a Lm128C mAGNET vector (see 
Figure 15 A,B). We later implanted a head bar and 3 mm diameter sterilized imaging 
window centered over the injection site in motor cortex (Figure 16A). During in vivo 
calcium imaging recordings, mice were awake, head-fixed and engaged in voluntary 
locomotion on a spherical treadmill [176, 177], positioned under a wide-field fluorescence 
microscope (Figure 16B). The imaging set-up is depicted in Figure 15C (see Methods for 
details). We performed two 20-minute long recording sessions, ~3-4 weeks after the initial 
virus injection.  
We motion corrected Ca recordings, manually selected ROIs from the maximum-
mean fluorescence intensity images (Figure 16E), extracted the normalized fluorescence 
intensity traces for these ROIs, and identified individual Ca events (see Methods for 
details). Consistent with the trend observed in the post-fixed brain slices (Figure 15), 
calcium recordings from CamKIIα mice contained ~10X as many ROIs (GCaMP6f 
expressing neurons) as recordings from Lm128C mice (Figure 16E, right vs. left). 
Representative traces for a CamKIIα vs. Lm128C cell are shown in Figure 16F (top), with 




neurons, compared to the total CamKIIα population (Figure 16G).  
Individual Ca event waveforms are shown for the same representative CamKIIα 
and Lm128C traces in Figure 16F (bottom), with the average Ca waveform for the ROI 
depicted in black. We found that the rise and fall times for ROI average waveforms are 
significantly shorter for Lm128C neurons compared to CamKIIα (Figure 16 H,I), 
suggesting that these neurons exhibit faster intracellular calcium dynamics. Furthermore, 
Lm128C neurons show significantly elevated pairwise correlation with other Lm128C 
cells, when compared to the total population of CamKIIα neurons (Figure 16 J). 
Interestingly, the features exhibited by Lm128C neurons, including elevated event 
frequency, faster event dynamics and greater synchrony, are typically associated with non-









Figure 16. In vivo calcium imaging of CamKIIα and Lm128C neurons in motor cortex.   
A) Schematic of imaging window and head bar implanted on the mouse head. (B) In vivo calcium imaging 
paradigm: animals were awake and head-fixed such that they could engage in voluntary locomotion on a 
spherical treadmill positioned under the imaging microscope. Two USB motion sensors allowed movement 
tracking. (C) GCaMP6f imaging set-up using a 460 nm LED. (D) Experimental timeline followed for in vivo 
calcium imaging. The same timeline was followed for CamKIIα and Lm128C mice. (E) Representative wide-
field images from in vivo calcium imaging recordings (max-mean pixel intensity across all frames) for a 
CamKIIα mouse (left) and a Lm128C mouse (right). Top: GCaMP6f fluorescence. Bottom: GCaMP6f 
fluorescence overlaid with manually identified ROIs (GCaMP6f expressing neurons). (F) Representative 
calcium event traces (top) and waveforms (bottom) from a CamKIIα neuron (left) and a Lm128C neuron 
(right). Black traces (bottom) represent the average event waveform and the red line indicates the average 
activation threshold. (G) Calcium event rates (events/min) for CamKIIα and Lm128C neurons. See Methods 
for description of calcium event identification. (H) Event rise time (s) for CamKIIα and Lm128C neurons. 
Event rise time was calculated as the time from fluorescence intensity increase above activation threshold 
(mean intensity of the waveform plus one standard deviation) to peak event intensity. (I) Calcium event fall 
time for CamKIIα and Lm128C neurons. Event fall time was calculated as the time from the peak event 
intensity to the point when intensity decreased below the threshold. (J) Intra-population pairwise correlation 
in events for Lm128C and CamKIIα neurons. See Methods for calculation of pairwise correlation. Data in 
(G)-(I) is averaged across recording sessions (n=10 recording sessions, 2 recording sessions per mouse) and 





4.3.3 CamKIIα and Lm128C motor cortex neurons are differentially modulated by 
movement 
 Throughout calcium activity recordings, movement data was collected by tracking 
the motion of the spherical treadmill using two motion sensors (see Figure 15B and 
Methods). Aligning the calcium traces to movement data allowed us to determine 
differences in the activity of these motor cortex neuron populations during periods when 
the animal was moving at high speed versus low speed. Figure 17A depicts representative 
examples of mouse movement speed throughout in vivo recordings, as well as examples of 
calcium traces for individual neurons during periods of high-speed movement (red) versus 
low-speed movement (green). We found that Lm128C neurons exhibited significantly 
elevated event rate during periods of high-speed movement (Figure 17Bii), while CamKIIα 
neurons exhibited slightly but not significantly elevated event rate during periods of low-
speed movement (Figure 17Bi). Furthermore, the total CamKIIα population exhibited 
significantly greater pairwise correlation in calcium activity during periods of high-speed 
movement (Figure 17Ci), while the pairwise correlation of Lm128C cells did not differ at 
high versus low speed (Figure 17Cii).  
4.3.4 Lm128C neurons exhibit biophysical properties that are characteristic of fast-
spiking interneurons  
In order to further characterize the biophysical properties of Lm128C cells, we 
performed two-photon guided patch clamp electrophysiological recordings of Lm128C and 
CamKIIα neurons within the same brain slices. Motor cortex brain slices from two 




physiology. We identified CamKIIα cells that were positive for GCaMP6f only, and 
Lm128C cells that were positive for both GCaMP6f and mRuby2 (see Figure 15A). We 
limited our electrophysiology analysis to neurons within ~250 µm of the brain surface 
(primarily layer 2/3 cells, as very few labelled cells appeared in layer 1), to match the cells 
recorded during in vivo calcium recording experiments. 
Figure 18A depicts representative voltage responses to stepped current for 
CamKIIα cells (shown in blue) and Lm128C cells (shown in orange). The slope of the 
spike frequency-current (f-I) relationship was much higher for Lm128C cells (Figure 18A-
C), consistent with the greater event rate for Lm128C cells observed during the in vivo Ca 
imaging experiment. Consistent with the faster peak spike frequency rates and greater gain, 
the average spike half-width for Lm128C cells was much narrower than for CamKIIα cells 
(Figure 18Di, iii), and the rate of spike decay was significantly greater for Lm128C (Figure 
18Dii), also consistent with the results seen in vivo. Together, these results demonstrate 
that the biophysical properties of Lm128C neurons resemble those characteristic of fast-







Figure 17. Calcium activity of CamKIIα and Lm128C motor cortex neurons during periods of 
high- and low- speed movement.  
(A) Representative examples of mouse movement speed throughout an in vivo calcium imaging recording, 
for a CamKIIα mouse (i) and a Lm128C mouse (ii). Periods of high-speed movement are highlighted in red, 
and periods of low-speed movement are highlighted in green. We define high-speed movement as 5 cm/s or 
greater for at least 1 second, and low-speed as less than 5 cm/s for at least 1 second. (B) Event rate (events 
per minute) during periods of high-speed and low-speed movement for CamKIIα (i) and Lm128C (ii) 
neurons. (C) Intra-population pairwise correlation of calcium events during periods of high-speed and low-
speed movement for CamKIIα (i) and Lm128C (ii) neurons. Figures present mean ± standard errors 






Figure 18. Electrophysiological properties of CamKIIα and Lm128C neurons.  
(A) Representative voltage responses (top) of a CamKIIα neuron (blue) and a Lm128C neuron (orange) to 
stepped current injection (bottom). The electrophysiological properties of sampled CamKIIα cells represent 
typical pyramidal cell-type behavior, while Lm128C traces are similar to fast spiking interneurons. (B) Firing 




(C) FI gain, calculated as the change in firing frequency from lowest firing rate to highest firing rate was 
divided by the amount of current injected. (D) i. Representative average spike shape of a CamKIIα neuron 
(top-blue) and Lm128C neuron (bottom-orange). Dots represent spike threshold and points corresponding to 
voltage mid-point used for calculating spike half-width. Faster, narrower spike with more after 
hyperpolarization are characteristics of fast firing interneurons. ii. Rate of spike decay for CamKIIα and 
Lm128C neurons. Rate of decay corresponds to time for voltage change from the peak to minimum value of 
the first derivative. iii. Spikes half-width, calculated as the time between half-amplitude voltages (voltage at 
the mid-point of spike peak and spike threshold). Reported p-values were calculated using a student’s t-test.  
 
4.3.5 Immunofluorescence reveals that Lm128C cells colocalize with CamKIIα, PV, and 
GABA 
 Both the in vivo calcium imaging recording and patch clamp electrophysiology 
results suggest that Lm128C cells resemble FSIs. Therefore, in order to further characterize 
Lm128C neuron identity, we performed immunofluorescence staining on brain slices from 
Lm128C animals. Staining with an anti-CamKIIα antibody confirmed that 98 ± 2% of 
Lm128C neurons do express CamKIIα (Figure 19 A,F), eliminating the possibility that 
FSI-like cells were labelled due to leaky promoter expression. Next, we performed 
immunostaining against parvalbumin (PV) – a calcium binding protein that has been shown 
to express in FSIs, and a commonly used genetic marker for these cells. Interestingly, only 
49 ± 4% of Lm128C cells express PV (Figure 19 B,F). Staining with an antibody against 
the inhibitory neurotransmitter GABA similarly revealed that 49 ± 6% of Lm128C cells 
are GABAergic (Figure 19 C,F). In order to further clarify these results, we also performed 
co-staining with combinations of the immunofluorescence markers (Figure 19 D,F). We 
were able to image the overlap of immunofluorescence of PV with either CamKIIα or 
GABA. We found that in superficial motor cortex (within ~250 µm of the brain surface, 
the maximum range of in vivo calcium imaging recordings), 43 ± 2% of PV+ neurons co-




GABA (Figure 19 E,G). These results suggest that Lm128C cells include a population of 




Figure 19. Immunofluorescence characterization of Lm128C neurons in mouse motor cortex.  
A) Representative confocal images of GCaMP6f fluorescence from Lm128C cells, immunofluorescence of 
a CamKIIα marker, and colocalization. (B) Representative confocal images of GCaMP6f fluorescence from 
Lm128C cells, immunofluorescence of a PV marker, and colocalization. (C) Representative confocal images 
of GCaMP6f fluorescence from Lm128C cells, immunofluorescence of a GABA marker, and colocalization. 
(D) Representative confocal immunofluorescence of a PV marker and a CamKIIα marker, and colocalization. 
(E) Representative confocal images of immunofluorescence of a PV marker and GABA marker, and 
colocalization. Note: (A-E) white arrow indicate neurons that co-localize with the antibody marker. Confocal 
image stacks for (D) and (E) were taken away from the injection site. (F) Quantification of the colocalization 
of Lm128C neurons with immunofluorescence markers. (G) Quantification of the colocalization of PV 
immunofluorescence with CamKIIα or GABA immunofluorescence. Note: all immunofluorescence 
characterization was performed on neurons within superficial motor cortex (~250 µm of the brain surface), 
within the range of in vivo calcium imaging recordings. Each comparison includes at least 50 neurons from 




Here, we have demonstrated microRNA-based neuron subtype classification by 




low expression of miR-128. The Lm128C cell population exhibits many unique 
biophysical properties and activity patterns in comparison to the overall CamKIIα 
population, and includes a subset of GABAergic PV+ interneurons that also express 
CamKIIα+.  
It is interesting to observe the expression of CamKIIα in GABAergic PV+ 
interneurons, which has not previously been identified. Over the years, in situ hybridization 
and immunolabelling of CamKIIα and glutamic acid decarboxylase-1 (GAD, the rate-
limiting enzyme for GABA production) in the mammalian cortex have suggested that these 
proteins are expressed in mutually exclusive cells [19, 20]. For these reasons, CamKIIα 
has come to be associated with cortical excitatory cells. Similarly, PV has been widely 
adopted as a marker gene for a subset of GABAergic cells known as fast-spiking 
interneurons (FSIs)[163], and has therefore been assumed to not express CamKIIα. 
However, CamKIIα and GAD are known to colocalize in neurons within other brain 
regions, such as the stria terminalis and cerebellum [19, 174]. Several recent studies 
suggest that there may be greater heterogeneity and overlap between cortical neurons 
expressing excitatory and inhibitory markers than previously thought. For example, 
Nathanson et al reported that some GAD67+ neurons were labeled in mouse somatosensory 
cortex with the CamKIIα promoter delivered from an AAV2.1 vector [86], although they 
did not further characterize these cells. Furthermore, single-cell transcriptomic profiling of 
cortical neurons has recently been used to identify 7 transcriptionally distinct subsets of 
PV+ neurons in mouse primary visual cortex [25], and acknowledged the existence of cells 




as inhibitory markers Gad1, Gad2 and PV [25].  
 The fact that we found some inhibitory neurons, though small in number, that 
express CamKIIα demonstrates that CamKIIα is not as specific for excitatory neurons as 
previously thought. Although CamKIIα has been associated with principal excitatory 
neurons in the mammalian cortex, its function is not inherently related to excitatory 
neurons. CamKII is a phospho-serine kinase whose activity is known to be critical for the 
induction of post-synaptic LTP [21]. While extensive work has been directed towards the 
involvement of CamKII in LTP at excitatory synapses, this does not preclude the 
involvement of CaMKII mediated LTP in interneurons. In fact, interneurons, and PV+ FSIs 
specifically, have been shown to exhibit post-synaptic plasticity [22, 23]. While some of 
the observed plasticity in interneurons can be explained by pre-synaptic mechanisms, it is 
plausible that CamKII-dependent post-synaptic LTP contributes to plasticity at excitatory 
synapses in interneurons.   
 In summary, we have labelled and characterized of a novel subset of CamKIIα+ 
neurons on the basis of miRNA profile (low miR-128) and revealed that these cells overlap 
with GABAergic PV-expressing FSIs in mouse motor cortex. This study provides the first 
example of a neural subtype classified on the basis of miRNA profile, and it opens the door 
for a new avenue of mAGNET neurotechnologies. As single-cell analysis tools provide 
increasing insight into neuron genetic diversity, including miRNA profile data, we expect 
that miRNAs will emerge as important biomarkers. Furthermore, as the regulation 
networks of individual miRNAs are further explored, this will in turn allow the design of 








Viral vector cloning. Standard molecular cloning procedures (PCR and restriction 
enzyme digestion) were used to construct AAV vectors. To produce AAV-CamKIIα-
GCaMP6f, the 1.3 kb CamKIIα promoter obtained from Ed Boyden (Addgene plasmid 
#64545) and the 1.35 kb GCaMP6f gene obtained from Douglas Kim (Addgene plasmid 
#40755 [43]) were amplified via PCR and inserted between the ITRs of an AAV-2 genomic 
vector obtained from Roger Tsien (Addgene plasmid #50954 [151]) via EcoR-I, Asc-I and 
Spe-I restriction sites. To produce AAV-CamKIIα-GCaMP6f-4X128, four instances of the 
miR-128 recognition site (exact reverse complement of the mouse miRNA sequence) were 
added to the 3’ UTR of the GCaMP6F transgene by annealing single-stranded DNA 
oligonucleotides synthesized by IDT DNA and cloning into NotI sites. To produce AAV-
CamKIIα-mRuby2-4X128, the mRuby2 reporter obtained from Michael Davidson 
(Addgene plasmid #54771 [184]) was PCR’d and used to replace GCaMP6f in AAV-
CamKIIα-GCaMP6f-4X128 via Asc-I and Spe-I sites. For viral vector sequences, see 
Supplementary Table 1. All new viral vectors produced here will be deposited to Addgene.  
Virus preparation. Recombinant AAV2.9 was packaged via triple transfections of 
the AAV-2 transfer vector (AAV-CamKIIα-GCaMP6f, AAV-CamKIIα-GCaMP6f-
4X128, or AAV-CamKIIα-mRuby2-4X128), cap-9 plasmid encoding the Rep and Cap 
proteins (serotype 9), and pXX680 helper packaging plasmid, into HEK293FT cells 




MIR 2700). Two days post-transfection, HEK cells were washed and lysed via multiple 
freeze-thaw cycles and sonication, and virus was purified from the lysate via PEG 
precipitation (System Biosciences, LV810A-1). Viral titer was determined via rt-PCR 
(Takara, AAVpro Titration Kit Ver.2) to be ~2E12 vg/mL. Viral transduction was first 
tested in primary rat neuron cultures before in vivo injections were performed.  
Animal Surgery. All procedures were done in accordance with the National 
Institutes of Health Guide for Laboratory Animals and were approved by the Boston 
University Institutional Animal Care and Use and Biosafety Committees. First, a surgery 
was performed to inject a mixture of AAV viruses. Mice were adult female C57bL/6 wild 
type mice (Taconic Biosciences) eight weeks old at time of virus injection. AAV viruses 
(AAV-CamKIIα-GCaMP6f + AAV-CamKIIα-mRuby2-4X128 OR AAV-CamKIIα-
GCaMP6f-4X128 + AAV-CamKIIα-mRuby2-4X128) were pre-mixed at equal particle 
numbers. Next, 2.5E8 vg each virus (~600 nL total) was injected in motor cortex (+1.250 
ML, +1.500 AP, -0.500 DV). Seven days after the first surgery, mice underwent a second 
surgery for implantation of a sterilized custom imaging window that was previously 
assembled. The window consisted of a stainless steel imaging cannula (OD: 0.317 mm, ID: 
0.236 mm, height 2 mm), fitted with a circular coverslip (size 0; OD: 3mm) adhered using 
a UV-curable optical adhesive (Norland Products). To access the motor cortex, the skull 
directly above the injection site was carefully removed with a dental drill, then the imaging 
window was placed flush against the brain tissue and secured in place with Kwiksil and 
acrylic cement. During the same surgery, a custom aluminum head plate was attached to 




Calcium imaging data acquisition:  
Animal habituation. Following full recovery from the second surgery, animals were 
habituated to being head-fixed and running on a 3D treadmill located under a microscope 
imaging apparatus. The mice were habituated for 5 minutes, 10, 15 and 20 minutes per day 
respectively for four days.  
Image Acquisition with sCMOS cameras. Animals were positioned underneath the 
microscope, and imaged while freely navigating the spherical treadmill. Image acquisition 
was performed via custom microscope equipped with a scientific CMOS (sCMOS) camera 
(ORCA-Flash4.0 LT Digital CMOS camera C11440-42U; Hamamatsu, Boston, MA). 
GCaMP6f fluorescence excitation was accomplished with a 5W LED (LZ1-00B200, 460 
nm; LedEngin, San Jose CA).  Custom microscope included a Leica N Plan 10X 0.25 PH1 
microscope objective lens, a dual band excitation filter (FF01-468/553-25), a dichroic 
mirror (FF493/574-Di01-25x36), and a dual band emission filter (FF01-512/630-25; 
Semrock, Rochester, NY), and a commercial SLR lens focused to infinity as the tube lens 
(Nikon Zoom-NIKKOR 80-200mm f/4 AI-s). A custom MATLAB script was used to 
trigger frame capture and to synchronize acquisition of image data with movement 
information. TTL trigger pulses were delivered to the camera using a common I/O interface 
(USB-6259; National Instruments, Austin, TX). Image acquisition was performed using 
HC Image Live (HC Image Live; Hamamatsu; Boston, MA). Because triggering was 
initiated using a software loop, the exact sampling intervals varied based on demands of 
the Windows 7 operating system. In general, the sampling rate was approximately 20Hz. 




page tagged image file format (mpTIFF’s). For a recording session of 20 mins, 
approximately 48 GigaBytes of image data were stored, spreading across 12 mpTiFF video 
files. The acquisition software was configured to buffer all frames in computer RAM 
during image acquisition to optimize acquisition speed. For each animal, full session 
recordings (20 min) were performed while monitoring GCaMP6f fluorescence using the 
specifications noted above.   
Movement data acquisition. Movement data was acquired as described in Gritton 
et al. [177]. The spherical treadmill was constructed following the design of Dombeck et 
al.[176]. Briefly, the treadmill consisted of a 3D printed plastic housing and a Styrofoam 
ball supported with air. Movement was monitored using two computer USB mice sensors 
affixed to the plastic housing at the equator of the Styrofoam ball. Each mouse sensor was 
mounted 3-4mm away from the surface of the ball to prevent interference of ball 
movement. The LED sensors projected on the ball surface 78 degrees apart. The x- and y- 
surface displacement measured by each mouse was acquired using a separate computer 
running a Linux OS (minimal CentOS 6), and a simple multi-threaded python script that 
asynchronously reads and accumulates mouse motion events, and sends packaged <dx,dy> 
data at 100Hz to the image acquisition computer via a RS232 serial link. Packaged motion 
data were received on the imaging computer using a Matlab script that stored the 
accumulated motion between frame triggers synchronized to each acquired frame.  
Calcium imaging data analysis:  
Image Pre-processing: contrast enhancement, motion correction and baseline 




imaging session, we first generated a reference image by projecting the mean values of 
every pixel in the first file. We then performed a series of imaging processing procedures 
to enhance the contrast and the characters of the image. We removed the low-frequency 
component (potential non-uniform background) with a Gaussian filter (python scipy 
package, ndimage.gaussian_filter, sigma=50). We then enhanced the boundaries of the 
high intensity areas to sharpen the image as previously described [185]. In brief, we low-
pass filtered the image with a Gaussian filter twice at two levels (sigma = 2 and then 1). 
The intensity differences in two filtered images, which represent the boundaries of high 
intensity areas, were multiplied by 100 and added back to the first low-pass filtered image 
(sigma = 2), resulting in a boundary-sharpened image. Finally, to prevent the potential 
bleaching that may affect the overall intensity of whole image, we normalized the intensity 
of each image by shifting the mean intensity to zero and divided by the standard deviation 
of the intensity. We then calculated the cross-correlations between the enhanced reference 
image and each frame to obtain the displacement between the location of max coefficient 
and the center of the image. For each frame, the shift that counter the displacement was 
then applied to the original, unenhanced image to complete the motion correction.  
Region of Interest (ROI) identification. While several semi-automatic algorithms 
have been developed for ROI identification, including those described in [186]  [186-188], 
these programs were not sufficiently robust to identify all neurons for our purposes. 
Therefore, we used manual ROI identification. After motion correction, using the 
maximum-minus-mean fluorescence of each pixel, we generated the maximum-minus-




on visual inspection of morphology. The center of each neural soma was registered using 
a circle with a radius of 6 pixels, corresponding to 7.8 microns.  
ΔF/F time series calculation. Raw fluorescence traces for each ROI were extracted 
from motion-corrected video using a custom Matlab script. For each ROI, we also 
normalized the trace by shifting the mean value to zero and scaling so that the maximum 
intensity equals 100.  
Calcium event identification and waveform calculations. The onsets of Ca events 
are correlated with a brief increase in oscillatory power at low frequency range, and 
therefore we used this as an indicator to detect Ca events. We first calculated the 
spectrogram from raw Ca2+ trace (Matlab chronux, mtspecgramc with tapers=[2 3] and 
window=[1 0.05]), and averaged the oscillatory power below 2 Hz. To detect any 
significant changes in power, we calculated the change in the power at each time point, and 
identified the outliner (Matlab function isoutliner).  For outliners that occurred at 
consecutive time points, we only choose the first outliner, as it represents the start of the 
change. We also only selected the positive outliners, as they represent the increase in the 
power. After identifying the time points of the significant increase in power, we then 
determined the end of power event by identifying the first time point where the power 
decreases.  
To obtain the peak and the start point of Ca events, we first extended the end point 
of the power event to the second time point with decreased Ca signal. After extension, the 
peak of Ca event was defined as the time point within the extended power event where the 




Ca signal between the peak and the start of the extended power. To ensure the quality of 
Ca events, we excluded any Ca events with an amplitude (the signal difference between 
the peak and the onset) less than 3 standard deviations of the trace in a 10 second time 
window prior to Ca event onset. In a few occasions, our event detection procedure may 
detect the same event more than once; therefore, we further refine the results by combining 
events that share overlapping time points. 
To calculate the rise and fall time of each Ca event, for each ROI, we aligned its Ca 
events to their peak and averaged the traces within 5 seconds before and after the peak as 
the representative waveform (length: 10 seconds). To calculate the rise and fall times of a 
waveform, we first calculated an activation threshold that is the mean intensity of the 
waveform plus one standard deviation. The rise time of the events for a ROI is defined as 
the time from when the intensity increases above threshold to the peak of the waveform. 
The fall time is the time between the peak and the time point when the intensity decreased 
below the threshold after the peak. We excluded any ROIs that did not have well-defined 
rise or fall times, such as the trace of the waveform did not fall below threshold after peak.  
Pair-wise correlation analysis between neuron pairs. We first binarized the Ca 
intensity trace by converting the time points within Ca event onset (identified above) to 
ones, and all other time points to zeros. The pairwise correlation coefficient from neuron 
A to neuron B is defined as the time points sharing ones in both A and B, divided by the 
number of total time points of ones in A. To obtain the representative pairwise correlation 
coefficient for each neuron, we averaged the pairwise correlation coefficient from the 




Movement data analysis:  
Movement data analysis was performed according to methods as described [177], with 
minor modifications.  
Spherical treadmill calibration. To map the Styrofoam ball movement to actual 
mouse linear velocity, we first calibrated the ball. We pinned the two sides of the ball at 
the equator perpendicular to each of the two computer mouse sensors, and then rotated the 
ball over a fixed distance perpendicular to the sensor to obtain the translation factors for 
calculating physical distance. The two computer mouse sensors were calibrated separately. 
Each computer mouse sensor reading was composed of a vertical reading and a lateral 
reading.  
Linear velocity calculation. We calculated the animal’s linear displacement in two 
perpendicular directions. One direction (Y-axis of animal movement), is calculated from 
the vertical reading of one sensor. The other direction (X-axis of animal movement) is 
calculated from the vertical readings of both sensors, using the following equations: 
 
𝑋 =




𝑌 = 𝑅 
 
Where L is the vertical reading from the left sensor, R is the vertical reading from the right 
sensor, and θ is the angle between the two sensors relative to the center of the ball that was 
fixed at 78 degrees. The change in linear distance were computed as: 𝐷 =  (𝑋2 + 𝑌2)
1
2. D 




triggered by TTL pulses as described above. To compute linear velocity, we divided the 
linear distance over time between sample points. We found that X, Y readings were in 
general smaller than 5 cm/s. X and Y readings were interpolated in the same way as 
fluorescence signals.   
Identification of sustained periods of movement with high and low linear velocity. 
We identified periods of high versus low linear velocity (speed) according to that described 
by Barbera et al. [189]. Briefly, we first smoothed each linear velocity trace using a low-
pass Butterworth filter with a low-pass frequency of 1.5 Hz, and then identified the time 
periods at which the smoothed linear velocity exceeded 5 cm/s for at least 1 second (Matlab 
commands “butter” and then “filtfilt” for zero-phase filtering). These periods were 
considered to be periods of high speed. Similarly, periods during which the smoothed linear 
velocity of the mouse stayed below 5 cm/s for at least 1 second were considered low speed 
periods. Periods continuous with the beginning or end of the session were excluded from 
further analysis. 
Calcium event properties across cell types during different movement periods. Ca 
events considered to be in the high or low-speed movement periods were used for event 
rate and pairwise correlation calculations, if the Ca event onset was during one of these 
time periods. Calcium event properties (event rate and pairwise correlation) were averaged 
for each ROI/neuron, and the differences between high- and low-speed time periods across 
all neurons were assessed using a paired t-test.  
Brain Slice Preparation for Electrophysiology. Coronal sections of motor cortex 




to in vivo calcium imaging recordings, as described above. Animals were anesthetized with 
isoflurane, decapitated and brains were removed in sucrose-substituted artificial cerebrospinal fluid 
(ACSF): 185 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 10 mM MgCl2, 25 mM NaHCO3, 12.5 
mM glucose, and 0.5 mM CaCl2. 400 µm slices were cut via Leica VT 1200 (Leica Microsystems) 
and incubated in 30°C ACSF consisting of 125 mM NaCl, 25 mM NaHCO3, 25 mM D-glucose, 2 
mM KCl, 2 mM CaCl2, 1.25 mM NaH2PO4, and 1 mM MgCl2, for 20 minutes and then cooled to 
room-temperature.  
Slice Electrophysiology. In order to differentiate between Lm128C (labelled with the 
red fluorescent marker mRUby2) and CamKIIα cells (labelled with green-fluorescent GCaMP6f), 
slice recordings were done using a two-photon (2P) imaging system (Thorlabs Inc.) with a mode-
locked Ti:Sapphire laser (Chameleon Ultra II; Coherent) set to wavelengths between 920 nm and 
950 nm, which was used to excite the Alexa Fluor 488, GCamP6f and tdTomato using a 20×, NA 
1.0 (Olympus) objective lens.  
Slice electrophysiology recording were done using a patch clamp electrode with 
tips (0.6–1 μm) pulled via horizontal puller (Sutter Instruments) and pipet resistance 
between 4 and 6 MΩ. Pipette were filled with intracellular fluid containing: 120 mM K-
gluconate, 20 mM KCl, 10 mM HEPES, 7 mM diTrisPhCr, 4 mM Na2ATP, 2 mM MgCl2, 
0.3 mM Tris-GTP, and 0.2 mM EGTA; buffered to pH 7.3 with KOH. Alexa Fluor 488 
hydrazid (Thermo Fisher Scientific) was added to this solution (0.15% weight/volume) to 
visualize the pipette under 2P.  
For each recording, pipette capacitance neutralization and bridge balance 
compensation were performed prior to breaking in. Data was acquired using Multiclamp 




10kHz. Access resistance of all recordings were 31.6 ± 5.2 MΩ (mean+/- standard error, 
n=XYZ cells). 
Electrophysiology Data Analysis. Brain slice electrophysiology data analysis was 
performed in python with custom written scripts using pyABF package. Spikes starts were 
identified by a threshold of 10 on their first derivative, with their peak as the maximum value. Spike 
half-width was taken as the time between half-amplitude voltages (voltage at the mid-point of spike 
peak and spike threshold). Rate of rise was calculated by dividing the change in voltage by the time 
from spike threshold to peak. Rate of decay corresponds to time for voltage change from peak to 
minimum value of the first derivative. In order to calculate the FI gain, change in firing frequency 
from lowest firing rate to highest firing rate was divided by the amount of current injected.  
Immunohistology. After the conclusion of in vivo calcium imaging recordings, 
animals were perfused with 4% PFA (except for animals used for slice electrophysiology). 
Brains were post-fixed in 4% PFA at room temperature for three hours, cryoprotected in a 
30% sucrose, then flash froze in OCT. Frozen brains were sectioned (coronal) at 50 μm on 
a cryostat, and slices were stored in PBS + 0.05% sodium azide. Brain slices were stained 
with antibodies against CamKIIα (Santa Cruz Biotech, sc-13082, 1:50), PV (SWANT 
GP72, 1:2000), or GABA (Sigma, A2052, 1:1000), followed by Alexa Fluor 633 goat anti-
rabbit or goat-anti-guinea pig secondary antibody (Invitrogen A21071, 1:1000 or 
Invitrogen A21105, 1:1000). All stained brained slices were imaged via confocal 
microscopy.  
Confocal Imaging and Quantification. Confocal imaging was performed on an 
Olympus FV1000 scanning confocal microscope, using a 10X lens or a 60X water 




slices. Consistent laser settings were used for all imaging sessions: 488 nm laser 3.5%, 350 
V; 543 nm laser 13%, 600 V; 633 nm laser 5%, 600V. GCaMP6f+ and/or mRUby2+ cell 
bodies were first identified throughout the stack, then compared to the stain and categorized 
as immunopositive or immunonegative. Immunopositive cell counts were pooled across 
slices stained for the same marker for each animal, and normalized to the total Lm128C 
cell count across those slices. In this way, the proportion (%) of Lm128C cells that 
colocalize with each immunomarker was calculated independently. For each animal, we 
analyzed at least 1-4 non-overlapping confocal stacks from 2-6 slices.  
 
4.6 Supporting Information 
4.6.1 Supporting Tables and Figures 
 
Table 4. Lm128C neuron colocalization with expressed and immunofluorescence markers 
Mouse 
Group Neuron Type  Marker Colocalizationb 
CamKIIαa 
 
mRuby2+ (Lm128C)  
(143) 
 
GCaMP6f+ (CamKIIα): (1334), 8 ± 2% 
Lm128Ca 
 
mRuby2+ (Lm128C)  
(495) 
 
GCaMP6f+ (Lm128C): (505), 98 ± 2% 
 





CamKIIα+: (201), 98 ± 2% 
PV+: (116), 49 ± 4% 





CamKIIα+: (161), 96 ± 2% 
GABA+: (213), 99 ± 1% 
 
a n =5 animals each 
b numbers in parentheses indicate the number of neurons analyzed across all animals (at least 50 per 








































































































































































































































































































CHAPTER 5 – CONCLUSION 
5.1 Summary & Significance 
5.1.1 Summary of dissertation findings 
 In summary, the work completed in this dissertation demonstrates the feasibility 
and utility of targeting and classifying neuron subtypes in the living mammalian brain 
based on microRNA expression profiles. The virally deliverable genetic classifiers used to 
implement this novel strategy have been designated “microRNA-guided neuron tags” or 
“mAGNETs.” 
 First, the feasibility of exploiting endogenous miRNA profiles was explored in a 
synthetic biology driven study of the principles underlying design of mAGNET genetic 
classifiers. In designing and testing proof-of-principle lentiviral mAGNETs to target 
cortical inhibitory (vs. excitatory neurons) in the mouse brain, we discovered that selected 
signature miRNAs should be expressed at a level of at least 1,000 raw sequencing reads, 
and should be at least 10-fold upregulated in off-target vs. on-target cells. Also, increasing 
the number of recognition site repetitions for a particular signature miRNA can improve 
targeting specificity, although there is a threshold between 4 and 12 repeats above which 
increased repetitions no longer improves targeting. Using combinations of signature 
miRNA sites has a more significant, synergistic impact on targeting specificity than 
increasing the number of recognition site repeats for one miRNA. Furthermore, we 
demonstrate that mAGNET gene targeting is brain region specific (due to differences in 
cell-type specific miRNA expression across differing brain regions), and does not disturb 




principle study achieved 83% targeting selectivity for the on-target, cortical inhibitory 
neuron population [135].  
 Next, we optimized the best mAGNET design from the first proof-of-principle 
study, to produce a highly specific neuroscience research tool for labelling cortical 
interneurons. Exchanging the Ef1α promoter for a more moderate, neuronal constitutive 
hSyn promoter improved lentiviral GABA mAGNET targeting specificity from 83 to 91% 
in the mouse cortex. Furthermore, switching from a lentiviral packaging system, which has 
a demonstrated transduction bias to excitatory neurons, to an AAV system using the AAV 
genomic vector pseudotyped with AAV 9 capsid protein (AAV2.9) reversed the 
transduction bias in favor of inhibitory neurons – thereby improving GABA mAGNET 
targeting specificity from 91 to 98% in mouse cortex. To illustrate the utility of this tool 
for neuroscience research, we demonstrated cortical interneuron targeting in a Ube3a 2XTg 
murine autism model, illustrated cross-species functionality in rats (a genetically 
intractable species), and performed virally mediated dual-color optogenetic manipulation 
of two separate neuron subtypes in the wt mouse brain.  Our optimized AAV GABA 
mAGNET provides a highly specific means of virally labelling cortical interneurons for 
neuroscience research [175].  
 Finally, we demonstrate the use of mAGNETs for classifying a novel neuron 
subset. During the course of developing GABA mAGNET, we observed a small fraction 
of off-target CamKIIα+ neurons that were persistently labelled using our vector that 
contained multiple recognition site repeats for miR-128, which was previously shown to 




characterize these low-miR-128-CamKIIα neurons in the mouse motor cortex using a 
newly designed Lm128C mAGNET. We found that Lm128C neurons constitute only 8% 
of the total CamKIIα neuron population in motor cortex. In vivo calcium activity imaging 
and slice electrophysiology experiments revealed that Lm128C cells exhibit many 
biophysical properties similar to fast-spiking interneurons, including elevated event rate, 
faster event dynamics, narrower waveform and greater synchrony. Immunofluorescence 
staining confirmed that half of Lm128C cells in superficial motor cortex express the FSI 
marker gene PV. Thus, Lm128C mAGNET enabled us to define and characterize a novel 
subset of cortical CamKIIα neurons that overlaps with FSIs in motor cortex [190].  
5.1.2 Significance for neuroscience research 
This work is novel in many respects, and is poised to have a significant impact 
across neuroscience, mammalian synthetic biology, and gene therapy fields. mAGNETs 
constitute the first demonstration of miRNA-based gene targeting to a specific neuron 
subtype (cortical inhibitory neurons). As brain-region-specific, neuron-type specific 
miRNA profiles before more readily available, the principles of microRNA cassette design 
outlined in this work can be used to target viral vectors to other neuron subtypes in the 
mouse and rat brain (and potentially other genetically intractable mammalian animal 
models, given the appropriate miRNA profiling). Importantly, we demonstrate the 
miRNA-based genetic targeting can achieve the same level of specificity as cell-type-
specific promoter or enhancer elements, enabling mAGNET targeting to neuron subtypes 
for which there is no easily identifiable marker gene.  




impactful for neuroscience research. Viral gene delivery is the preferred and sometimes 
only available means of cell-type targeting in genetically intractable species and human 
disease models. Thus, mAGNETs provide a much needed platform for allowing cell-type 
specific neural characterization in these animals.  
The GABA mAGNET specifically provides a means of virally labelling (and 
manipulation via GENS) of cortical interneurons. Due to their important functions in 
regulating and synchronizing principal excitatory neurons, cortical interneuron dysfunction 
is implicated in many brain disorders, for example in Autism spectrum disorders. GABA 
mAGNET provides a means of virally labelling these neurons in disease models, to 
facilitate the characterization of interneuron dysfunction within the context of disease state 
in the living brain.  
In addition to targeting known neuron subtypes, we demonstrated that miRNAs can 
be used to classify previously uncharacterized neural subsets. For example, mIR-128 is 
known to be involved in neuronal excitability, and deficiency of this miRNA has been 
linked to motor impairment. Thus, we used a mAGNET vector to label CamKIIα+ neurons 
(thought to be excitatory neurons) with low levels of mIRiR-128. Surprisingly, we found 
that Lm128C cells resemble cortical inhibitory neurons, and in fact half of them are 
GABAergic and express PV. Thus, miRNA-based neuron classification led us to discover 
a novel neuron subset and demonstrated that CamKIIα is expressed outside of cortical 
excitatory neurons. A similar approach can be applied for other miRNA with known 
regulatory functions, to elucidate more insights into the heterogeneity of neuronal cell 




delineating meaningful neuron subtypes.  
 
5.1.3 Significance for human gene therapy 
 Beyond applications in neuroscience research, mAGNET viral vectors have 
translatable potential for human gene therapy. Currently, the most efficient DNA delivery 
method for human gene therapy is the use of viral vectors, specifically LV and AAV [73, 
191]. Three viral gene therapies have been approved so far by the FDA [192-194], all 
within the past year. There are two main modes of viral gene therapy. The first is ex vivo 
cell therapy, in which either autologous or autonomous human cells are virally transduced 
and expanded in cell culture, then replaced or introduced into the human patient [192, 193]. 
The other is direct in vivo viral gene delivery [194]. Lentiviruses tends to be used in ex vivo 
gene therapy, partially due to its greater packaging capacity. However, the random 
integration of lentiviruses in the host genome has the potential to lead to deleterious 
outcomes such as cancer [191]. Therefore, AAVs are the viral vector of choice for in vivo 
gene delivery, as they do not integrate into the host genome but rather persist in an episomal 
state within the host cell nucleus [78].  
Just as in research applications, the limited payload of these viruses, especially 
AAV, poses a problem for therapeutic gene delivery [78]. There are several techniques that 
have been applied in attempts to overcome this issue. For example, in the dual-AAV 
approach, the genetic classifier construct is split into two halves which are each delivered 
in separate AAV particles, then reassembled via homologous recombination and/or trans-




dependence on both high co-transduction efficiency of the AAVs and highly efficient AAV 
genome reconstitution, which remain a problem. The mAGNET technique illustrated here 
for research purposes in the rodent brain, should be directly translatable for human gene 
therapy targeting in the CNS, as the miRNA profiles of disease states are elucidated. 
microRNAs are already being explored as diagnostic biomarkers [172] or gene therapy 
therapeutic agents [173], for example in Huntington’s disease, although they have yet to 
be implemented to target gene therapy expression. Given these current challenges and 
opportunities, the potential impact of mAGNETs for targeting viral gene therapies in the 
CNS could be significant.  
 
 
5.2 Future Directions 
In the future, there are many possible experiments that could help address some of 
the questions raised throughout the development of mAGNETs. As the cell-type specific 
profiles and regulatory functions of individual miRNAs are further explored and 
quantitative models of miRNA regulation improve [126], mAGNET classifiers can be 
designed for many neuroscience applications. For example, mAGNETs would be useful 
for targeting and monitoring dynamic phenotype changes in adult neurons. Such constructs 
incorporating highly variable signature miRNAs have been used to monitor neural stem 
cell differentiation [121]. In adult neurons, tools for monitoring phenotype changes include 
the transcription factor c-fos and the synthetic promoter E-SARE [122, 123], which broadly 
target cells with elevated activity patterns. With better understanding of the pathways 




dynamically monitor a wide range of specific phenotype changes in the adult brain. Finally, 
individual miRNAs are becoming increasingly linked to neurological and psychiatric 
diseases [130, 131, 197], and positive mAGNETs could prove an effective platform for 
targeting human gene therapies to specific populations of diseased neurons. 
Another interesting line of investigation would be to explore whether positive 
miRNA regulation can be encoded in a genetic classifier. Because miRNA regulation is 
inhibitory, up until now we have selected signature miRNAs to repress expression in off-
target cells. However, it would greatly improve the ease of mAGNET design to be able to 
choose signature miRNAs positively associated with the target cell type. A double-negative 
(positive) targeting strategy would greatly facilitate miRNA-based neuron targeting and 
classification applications in basic research. miRNA circuit inversion has been previously 
reported in cell culture [125],  and the same principles could be applied to develop double-
negative (positive) mAGNETs. Signature miRNAs specific to the target neurons should 
sufficiently knock down a tetracycline repressor fused to a Kruppel-associated box domain 
(tTR-KRAB) [198, 199], which in turn will repress a transgene in the same vector by 
binding to a tetO7 operator site [200] to produce positive mAGNETs. This chimeric 
repressor system has proven useful in eukaryotic applications over the past two decades, 
as it exhibits negligible interference with endogenous gene regulation [198, 199].   
Further exploration and characterization of the novel Lm128C neuron subtype we 
reported here could help clarify the prevalence and function of these cells. For example, 
Lm128C cells should be systematically labelled and quantified across cortical regions in 




could also be repeated also across mammalian species. A remaining question is whether 
PV- and PV+ Lm128C neurons exhibit different biophysical properties and constitute 
further subclasses of cells. To investigate the identity of the PV- Lm128C cells, an 
interesting future experiment would be to virally target GCaMP to both Lm128C and PV 
cells in the same animals and characterize the activity PV+ versus PV- Lm128C cells.  In 
order to gain insight into the functional properties of these neurons, they could potentially 
be labelled with anterograde and retrograde transport tracing vectors, to elucidate the 
upstream and connectivity patterns of Lm128C cells. Finally, it would definitely be 
interesting to test whether CamKIIα-mediated long term potentiation occurs in these cells.  
Additionally, one implication of the discovery of Lm128C cells is that CamKIIα is 
not as robust of a marker as previously thought for pyramidal excitatory neurons in the 
mammalian cortex. Therefore, precautions should be taken when using this promoter to 
target excitatory neurons. A mAGNET vector employing a CamKIIα promoter and 
recognition sites for miRNAs, such as miR-384-5p, 130a, or mIR-384-3p [92] that are 
highly expressed in cortical GAD+ compared to CamKIIα+ cells could be used to more 
specifically label cortical interneurons, especially when delivered in an LV vector. Overall, 
the mAGNET strategy reported here encompasses the first examples of microRNA-based 
neuron subtype targeting and classification, and opens the door to vast array of potential 
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